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Cachexia is often a vital consideration in assessing the 
survival prospects of cancer patients. Approximately two-
thirds of all patients with malignant disease are cachectic 
at first diagnosis or become so at a later stage. The effect 
of the cachectic condition on the course and outcome of the 
cancer therapy can be very significant. At present, however, 
little is known about the mechanisms that result in this con-
dition, its true frequency or heterogeneity, the extent of 
tumour involvement in causing metabolic alterations in the 
host or the secretion of ''ectopic factor(s)" acting on host 
tissues. There appears no simple correlation between the 
degree of cachexia and the typ e , size, site or degree of 
metastatic spread of the tumou r , but removal of the tumour 
has been associated withcompl ete reversion of the cachexia 
syndrome. 
An assessment of the degree of cachexia in certain cancer 
patients was undertaken. An epidemiological study involving 
anthropometric determination of the muscle and fat areas of 
52 cancer patients and 258 control patients showed that can-
cer patients, other than those with cancer of the breast, had 
significantly lower muscle and fat areas when compared on the 
basis of matched standard values. Breast cancer patients as 
a group are not cachectic and have increased fat and muscle 
areas, irrespective of whether they are in remission or have 
progressive disease. 
An in vivo study involving measurement of the arterial and 
arterio-venous concentration differences across the forearms 
of 12 cancer weight-losing patients; 8 noncancer weight-
losing patients and 9 normal controls was undertaken. A 
significant increase in the number of amino acids in venous 
excess was found in the weight-losing cancer patient group 
as compared with both other groups, suggesting that enhanced 
muscle proteolysis occurred in the cancer patients or 
(ii) 
alternately, that decreased utilization of amino acids by 
the muscle tissue i.e. decreased proteogenesis,was a factor 
in these patients. 
Rates of fat and muscle protein breakdown were determined 
in vitro in tissue incubation systems; in the case of the 
latter, cell culture systems were also used, in order to try 
to determine a "direct" or ''indirect" effect of tumours on 
host tissue, possibly contributing to overall weight loss. 
There were no differences in the effects of serum, either 
"whole'' or desalted, obtained from weight-losing cancer 
patients and matched control patients, in respect of hete-
rologous promotion of lipolysis or proteolysis, and thus no 
evidence was apparent for the presence of "ectopic factor(s)". 
However, this model is not definitive due to methodological 
limitations, and the true causes of cancer-associated cachexia 
remain unknown except in those patients whose appetite or 
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CHAPTER 1 
THE FIELD OF CANCER CACHEXIA 
Cachexia, or inanition, has long been recognised as a leading 
cause of death in cancer (1). As many as two-thirds of all 
patients with malignant disease are cachectic at the time of 
first diagnosis or become so, at a later stage (2)~ Indeed, 
many cancer patients initially present with significant 
weight loss as their first and only symptom, in the face of 
an apparently adequate diet (3). In such patients, a 
reduced intake of food may later contribute to cachexia. 
Clearly, a substantial number of cancer sufferers lose body 
mass as a result of gastrointestinal disease which depresses 
the appetite, impairs dig e stion or causes malabsorption. 
There may also be anxiety-cau s e d anorexia, nausea produced 
b y drug a dmini s tration and po st-operative catabolic states. 
Cachexia is characterised pri ma rily by weakness, anorexia, 
depletion (and occasionally r ed i s tribution) of body tissues 
and an inability to maintain n ormal regulatory functions 
(4,5). There is no simple relationship between the degree 
of cachexia and the type, size, site or degree of metastatic 
spread of the tumour (4). 
The effects of cachexia on the course and outcome of cancer 
therapy is probably very significant. Median survival was 
signifLcantly shorter in the case of patients with weight 
loss than in that of patients presenting without loss of 
weight and chemotherapy response rates were also lower in 
the·patients with weight loss (6). The cachectic condition 
may even limit or preclude cancer therapy in certain instances 
( 7). 
Weight loss may arise as an indirect and mechanistically clear-
cut consequence of malignancy or it may be an apparently in-
explicable feature of the cancer-host relationship, as sugges-
ted by the lack of correlation that sometimes exists between 
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the degree of weight loss and various clinical parameters 
(8). Thus,Strain et al (9) have shown severe weight loss 
to occur (up to 25% body weight) in rats bearing a xeno-
grafted hypernephroma from a weight-losing human patient 
treated by surgical removal of his tu~our. Dietary intakes 
were not decreased and malabsorption contributed little, if 
anything, to the loss of weight observed in these animals. 
This situation is very similar to that very commonly observed 
in spontaneous tumour malignancies. 
Removal of tumours by surgical procedure or regression brought 
about by other treatment modalities have often been associated 
with complete reve rsion of the cachexia syndrome (10). 
The mechanisms by which single tumours may cause the loss of 
body tissue and other metabolic alterations in their hosts 
is not k nown at this time. Various proposals have, however, 
been made based on diverse lines of research and clinical 
observa t ion, and these will be reviewed in this chapter. 
1.1. TUMOUR-HOST RELAT·IONSHIPS 
The ability of tumour cells to establish themselves in host 
tissue is inherently necessary for their survival. The 
growingtumour relies ?n thehost to supply all the require-
ments for cell replication and growth i.e. the precursors 
for protein and nucleic acid biosynthesis, as well as 
carbohydrate and lipid fuels to supply energy. The body 
fluids of the host provide a proximal source for these 
nutrients, the diet being a more distal source. 
In principle, tumours may be able to exert diverse systemic 
effects to ensure their survival in the competition for 
important metabolites and trophic factors. The generalized, 
inter-organ reaction of the host to the effects of the tumour 
may constitute part or most of the basis for the cachectic 
phenomenon seen in many cancer patients. 
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1.1.1. Tumour Effects on Protein Metabolism. 
Loss of total body protein, and in particular muscle protein, 
has been observed and quantified in both animal experimental 
models (11,12,13) and in cancer patients (14,15). Hypo-
albuminaemia is a common sign encountered in malignant disease 
and may often provide evidence for marginal protein malnutri-
tion in cancer patients (16,17). 
1.1.1.1. Tumours acting as ni t rogen 11 traps 11 • 
That tumours may act as nitro ge n "traps" was postulated by 
Mider (18) and has since been c onfirmed by many workers 
(16,17). Tumours have the capacity to take up nitrogen 
derived from host tissue proteins. Once with in the tumours, 
t his nitro gen is not releas ed again to the host tissues (16). 
Th e nitrogen con ten ts · of vario~s host tissues in rats bearin g 
Walker 256 carcinoma s were f ou~d to be decreas e d by Sherman 
et al (13). Si milar r e sul ts · . .;e re obtained in rabbi ts carry-
ing Brown - Pierce carcinomas (1 7 ). Costa et al (14), however, 
reported no changes in the ni trogen content of muscles from 
cancer patients compared with t issue obtained from controls. 
There is no reason to believe t hat tumours cannot consume 
both exogenous (dietary) nitrogen and nitrogen from endogenous 
sources (17). An idea put f o rward by Sherman et al (13) is 
that dietary nitrogen is the major nitrogen source for tumours, 
during a short period of initial growth, but that thereafter 
the dietary intake may frequently be inadequate, so that dis-
pensable stores of nitrogen from various host tissues are 
given up to meet the increasing needs of the tumour. This 
is clearly a somewhat simplistic notion in view of the in-
tegrated nature of whole body nitrogen metabolism. 
Nitrogen balance studies in cancer patients have so far been 
equivocal, and a considerable variation in the picture from 
patient to patient must be anticipated (13,17). 
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1.1.1.2. Uptake of amino acids by tumours. 
Tumour requirements for amino acids are influenced by the 
apparently slow rate at which non-essential amino acids are 
synthesized, by tumour tissues in vivo (16). Generally, 
amino acid requirements of tumour cells are beyond their 
own synthetic ability and there is therefore a demand on 
the host to provide essential and many non-essential amino 
acids. Glutamine, for example, is hardly detectable in 
tumour cells (16) and must be considered to be an absolute 
requirement. Tumour cell membranes appear to be readily 
permeated by this amino acid (19). Factors that may favour 
uptake of amino acids from the host are not known, but for 
those amino acids present at low concentration within 
tumour cells, a gradient may operate to promote efficient 
uptake of these essential nutrients. 
The availability of the host amino acid pool is thus probably 
a factor of great importance for tumour nutrition. Hence 
systemic effects exerted by tumours may well influence the 
rates of proteolysis and proteogenesis in host tissue. 
Tumours have a unique capacity to grow in starvin g animals 
and to concentrate amino acids under extremely adverse con-
ditions (16). 
1.1.1.J. Increased protein degradation in the tumour-bearing 
host. 
Increased degradation of muscle proteins has been observed 
by Lundholm et al (15) in cancer patients and in tumour-
induced mice. A tumour-associated increase in some lyso-
somal enzyme activities was also found: cathepsin-D and 
s-glucuronidase activities were increased, while acid phos-
phatase activity remained unchanged. 
The simultaneous increase in lysosomal enzyme activity in situ 
and in the fractional degradation rate of muscle proteins in 
cancer patients may thus point to a role of these host tissue 
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enzymes in the development of cachexia. 
Clarke et al (20) failed to detect signs of excessive protein 
catabolism in the muscle tissue of five patients with prog-
ressive disease. The peripheral amino acid levels were 
measured and no evidence of an increased venous excess was 
found. 
1.1.1.4. Decreased protein synthesis in the tumour-bearing 
host. 
Isolated diaphragms derived from rats bearing Walker 256 
carcinomas incorporated less [3H)-4,5-lysine into myofibrillar 
proteins than did the muscle tissue of controls (12). A 
''toxohormone" preparation from the tumour itself, added to 
the incubation medium of control rat hemi-diaphragm pieces, 
decreased the uptake of the la belled amino acid. This 
also happened when the material was injected into live con-
trol rats, and theincorporation of thelabelled amino acid 
into hemi-diaphragm pieces prepared from these animals was 
measured (12). 
Goodlad and Clarke (11) have found an inhibition of Pm-lysine 
incorporation in polyribosomal preparations from gastro-
cnemius, but not soleus, muscle of tumour-bearing animals. 
Their results indicated that the inhibition of protein syn-
thesis occurred at the level of translation. Lundholm et 
al (21) have shown significantly decreased incorporation of 
radioactive leucine into skeletal muscle proteins in homog-
enates prepared from muscle material derived from cancer 
patients. Amino acid addition stimulated leucine incorpora-
tion, when the enrichment was effected at ten times the con-
centration of the individual amino acids in human plasma. 
They proposed, on the basis of this amino acid stimulation, 
that the decreased protein synthes~s observed was not due to 
any defect in the mechanism for initiation, elongation or 
termination of protein biosynthesis. 
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The ability of added amino acids to restore the incorporation 
of label into muscle protein to control levels, suggests 
that amino acid unavailability may be the reason for dec-
reased overall protein synthesis, in preparations not supple-
mented with added precursors. The ability of tumours to 
deplete the amino acid pools of their hosts may be brought 
about not only through sequestration of amino acids but 
also as a result of general stimulation of gluconeogenesis, 
in the host. A full amino acid complement for protein 
biosynthesis may consequently not be available to the host 
(12,20). This would decreas e the overall rate of protein 
synthesis and increase the concentration of amino acids in 
the body available to the tumour, or an acceleration of 
host gluconeogenesis may be brought about. Specific re-
quirements of tumour s for particular amino acids (e.g. 
glutamine and asparagine) and their facilitated uptake into 
tumour cells (19), would support this concept, although no 
evidenceis available to show that preferential sequestration 
of amino acids by tumours o ccurs . The constant turnover 
of proteins, in the steady state, in the ho st would enable 
tumours to sequester the amino acids released from host 
tissues without any direct effect on the net protein content 
of host tissues. 
1.1.2. Tumour Effects on Lipid Metabolism. 
1.1.2.1. Lipid requirements of tumours. 
The available evidence on the rate and sufficiency of syn-
thesis of lipids by tumour cells is equivocal. Most experi-
ments have dealt with synthesis of lipids in vitro and may 
thus not relate to the in vivo situation (16). 
Tumours are thought to utilize host cholesterol and fatty 
acid stores and not to accumulate these lipids to any great 
extent (17). The exact role of lipids in tumour metabolism 
is not known, but it is certain that cholesterol plays a 
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structural role and is ·assimilated into tumour membranes. 
As an energy source, fatty acids appear to play a minor 
role. Experiments suggesting tumour oxidation of mobilized 
lipids have been performed mostly in vitro under aerobic con-
ditions (22). In~. tumour cells . are frequently in a 
relative and varying state of hypoxia and are generally, al-
though not universally, capable of maintaining high rates of 
glycolysis even in the presence of oxygen (23). The primary 
energy source of tumour cells is thus glycolysis. 
1.1.2.2. Loss of body fat in tumour-bearing hosts. 
Swiss mice bearing Krebs-2 carcinomas have displayed profound 
and sustai ned fat lbss during tumour growth (24). This dep-
letion of body fat occurred in three phases: an initial 
rapid phase when 50% of body fat was lost even though the 
tumour was barely detectable; a second phase of steady-state 
fat loss when tumour growth was rapid; and a third terminal 
phase, characterized by subs tantia l fat lo ss . The authors 
proposed that a lipolytic fac tor caused the initial phase of 
fat loss but provided no evidence for the factor. 
Work done on compositional changes in human muscle during 
malignant growth hav e shown that the muscles of cancer 
patients have a fat content, per unit wet mass, that is 50% 
lower than that of muscles from control patients (14). 
Kralovic et al (25) using rats bearing Walker-256 carcinomas, 
showed a reduction of total body neutral lipid when tumours 
reached a mass equal to about 6-7% of total body mass, but 
no host lipid loss was observed when tumours were at about 
4% of the host body mass. 
1.1.2.J. Increased plasma fatty acid concentrations in 
tumour-bearing hosts. 
Increased concentrations of unesterified plasma free fatty 
acids have been observed in cancer patients, as a group, 
when they were compared with non-cancer patients. Those 
a 
patients with active metastatic disease showed individually 
increased plasma free fatty acid levels (26). 
This effect has also been seen in rats bearing induced 
tumours (27). 
Mays (22), in a detailed study of serum lipids in 15 cases 
of human cancer, was unable to confirm the finding of in-
creased fatty acid levels and concluded that, in the absence 
of liver dysfunction, plasma fatty acid levels of far-advanced 
cancer patients remained within the normal range even though 
marked loss of fat depots occurred. Holroyde et al (8), in 
a study of eight cancer patients having progressive weight 
loss compared to six cancer patients having no weight loss, 
found no difference in plasma fatty acid concentrations. 
1.1.3. Tumour Effects on Car bohydrate Metabolism. 
1.1.3.1. Tumour c ell demand for glucose. 
Aerobic tumour cells do not appear to use the Krebs cycle 
to the same extent as do norm a l cells. Warburg (23), writin g 
authoritatively, at an early stage, on the metabolism of 
tumours, · stated that an absence or defect in the oxidative 
Krebs cycle is inherent in tumour cell metabolism. It has 
become widely accepted that cancer cells oxidise glucose 
very actively even in the presence of oxygen. Tumour cells, 
even those derived from gluconeogenic tissues, are incapable 
of synthesizing glucose (16). 
Lactate producing glycolysis does not produce as great an 
amount of energy as does complete oxidative catabolism of 
this carbohydrate; the needs of the tumours for a glucose 
source are, thus, considerable. Also, if intermediates of 
glycolysis such as glucose-6-phosphate and fructose-6-phosphate 
are channelled into the hexose-monophosphate shunt for the 
biosynthesis of purines, pyrimidines, DNA and RNA, a further 
demand for glucose is caused (28). The contribution to total 
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glucose metabolism of the hexose phosphate pathway in tumour 
cells in vivo has not yet been estimated, but it is known 
that the necessary enzymes are present (16). 
Tumour celis contain undetectable amo~nts of free glucose 
(17) and appear to lack a storage capacity for glucose (16). 
Tumours, therefore, function as glucose "traps" in order to 
survive (17). Rapid uptake of glucose by tumour cells may 
be the result of a change in the permeability of the cell 
membrane. Alternatively, a large glucose gradient may drive 
the monosaccharide into tumour cells, since glucose is lack-
ing in the cytoplasm. Many cancer patients show diabetic 
glucose tolerance (10,29,30,31). 
Episodes of hypoglyca emia in ca ncer patients and in tumour-
bearing animals have been rep or ted (17). On the other hand, 
many tumour-bearin g h9sts do not becom e hypo glycaemic (32). 
For exampl e , fasting blood glucose levels were normal in a 
group of we i ght-lo i ing canc e r patients seen in a study by 
Waterhous e and Kemperman (31). Maintenance of normoglycaemia 
in the face of increasing demand s for glucose by a growing 
tumour could be accomplished by altering the metabolism pat-
tern of the host, i.e. by increasing the gluconeogenic acti-
vity (32) or by using alterna t ive fuels, e.g. free fatty 
acids, thus "sparing'' glucose to be Used by the tumour. An 
increased dietary intake of glucose would also balance the 
hypoglycaemic strain of the tumour on the host. 
1.1.3.2. Increased glucose provision by the host. 
Glycogen Depletion. 
Depletion of glycogen stores in the muscles and liver of 
tumour-bearing hosts has been reported in the case of experi-
mental animals bearing a variety of tumours (17,32). However, 
a hypoglycaemic condition developed in rabbits bearing Brown-
Pierce carcinomas, showing substantial glycogen depletion 
(33). Thus the role of glycogen mobilization, in compensating 
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the hypoglycaemic pressure exerted by the tumour on the host, 
has been questioned. Shapot (17) provided evidence for a 
direct correlation between host liver glycogen depletion and 
the acceleration of liver gluconeogenesis. 
Increased glucose synthesis. 
The rate of gluconeogenesis is increased in many cancer 
patients (8,20) as well as in tumour-bearing animals (17). 
Singh et al (32) showed increased gluconeogenic rates in 
rats bearing transplantable sarcomas and treatment of the 
animals with an inhibitor of gluconeogenesis caused hypo-
glycaemia. The importance of an increased gluconeogenic 
rate in maintaining normal blood glucose levels was thus 
evident. 
Gluconeogenesis is a process which occurs in liver, kidney 
and probably in white muscle tissue, under multihormonal 
control. Increased plasma levels of glucocorticoids in-
crease the activity of key enzymes in the gluconeogenic 
pathway, as do increases in growth hormone. Singh et al 
(32) were unable to establish that changes in key hepatic 
enzymes caused the increased gluconeogenesis observed. An 
alteration in insulin release or binding, or insulin in-
sensitivity, may lead to gluc9neogenesis. A defect in 
insulin release in cancer-bearing patients was reported by 
Jasani et al (30), but normal though delayed release was 
shown by Schein et al (10). Schein et al also showed 
normal insulin receptors to be present on monocytes, although 
a resistance to administered insulin was seen in cancer 
patients showing glucose intolerance. 
An effect of the tumour, therefore, on the various hormonal 
control points of gluconeogenesis can directly increase the 
glucose available to the tumour. The increased glucose demand 
of the tumour may deplete the glucose content of the plasma 
and of the tissue (glycogen) and physiological metabolic 
mechanisms in the host may then occur to increase gluconeo-
genesis. 
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Tumour effects on gluconeogenesis may also be indirect; 
thus an increasing substrate availability for gluconeogenesis 
(e.g. lactate or glucogenic amino acids) is known to increase 
the rate of glucose synthesis independently of other control 
mechanisms. Lactate does not accumulate in tumour cells, 
where it is also not metabolised (28). Transport of lactate 
into the plasma, to the liver of the host, results in gluco-
neogenesis and hence a cycling effect is set up between the 
tumour cells and the host liver cells. Increased glucose-
lactate-glucose (Cori cycle) activity has been seen in many 
weight-losing cancer patients (10,34). Increased proteo-
lysis and decreased proteogenesis in host muscles (as men-
tioned in preceding sections) increases the availability to 
the liver of glucogenic amino acids, such as alanine. The 
study by Clarke et al (20) on peripheral amino acid levels 
in cancer patients showed tha t alanine, glycine and threonine 
were decreased in arterial blood in the cancer patients, com-
pared with controls. The pr eferential use of some amino 
acids either by the tumour it self e.g. glutamine or aspara-
gine, or by increased host gluconeogenesis would serve 
further to decrease the synth esis of proteins, and thus to 
increase amino acid availability either for host gluconeo-
genesis or to the tumour. 
1.1.3.3. Glucose intolerance in tumour-bearing hosts. 
Normal fasting blood glucose levels were observed in weight-
losing cancer patients (31), who subsequently, on the admin-
istration of glucose, showed a delayed clearance of glucose 
which was ascribed to defective metabolic adjustment. These 
cancer patients were also found to continue fatty acid oxi-
dation after glucose administration i.e. they appeared to 
retain the metabolic patterns of the fasting state even in 
the fed state. 
Glucose intolerance is a widely observed phenomenon in cancer 
patients (10,29,30). The role played by defective insulin 
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release or action has not been clarified, and this type of 
mechanism cannot generally be said to account for the delayed 
glucose clearance seen in cancer patients. Lundholm et al 
(15) showed decreased glycolytic and oxidative enzyme acti-
vities in tumour-bearing mice and men .which supports previous 
suggestions from findings in man (21,31) that malignant 
tumours interfere with the ability of the host to utilize 
glucose. 
tolerance. 
This may then result in the observed glucose in-
The acceleration in the rates of g~uconeogenesis may be so 
great that hyperglycaemia may occur and this may contribute 
to a diabetic glucose tolerance curve. 
1.1.4. Tumour E~fects on Nucleic Acid Metabolism. 
A wide spectrum of tumours has been found to synthisize 
purines de nova from glycine, formate and other precursors. 
Preformed purines in the diet can be used by the tumour, as 
shown by Henderson and Le Page (16); thus considerable 
amounts of host purines were transferred to, and utilized 
by, several transplantable mouse tumours. 
Pyrimidine synthesis de .!!.£.Y2. has been less well studied in 
tumour cells, but the synthetic ability required for this· 
is present. Shapot (17) reported that rapidly growing 
malignant tumours primarily used the "salvage" pathway for 
pyrimidine acquisition. Different tissues of the host may 
preferentially use either the de .!!.2.Y.Q. or "salvage" pathway 
and host tissues may be differentially affected by the 
tumour-caused drain on the necessary precursors. Success-
ful competition of the tumour with the host for thymidine, 
as a precursor of DNA, has already been shown (17). 
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1.2. THEORIES AND PROPOSED MECHANISMS. 
The tumour, by its active metabolism and proliferation 
within the host may cause alterations in the metabolism of 
the latter, such that wasting and a catabolic state prevails. 
Alternatively, the tumour may elicit a more direct response 
from the host by secreting an ectopic "factor" that would 
induce a catabolic state. 
In accordance with the "indirect mechanisms", Gold (35) has 
proposed a mechanism for cancer cachexia dependent on an 
interplay of host gluconeogenesis and tumour glycolysis. 
The production of lactate by t h e tumour may have a two-fold 
significance. The energy produced by the formation of lac-
tate would constitute an energy source for the tumour, but 
since lactate formation produc e s significantly less energy 
per mole cul e of glucose than t h e corre spondin g oxidative 
pathway, Gold has proposed an a dditional reason for the ap-
parent obligatory production of lactate: lactate production 
enhances gluconeogenesis of t h e host. However, since gluco-
neogenesis occurs in host tissue and is an energy consuming 
process, an increased energy drain on the host is brought 
about and the result is the wasting of host tissues. 
This proposal is supported, in theory, by much of the evidence 
reviewed in the preceding sections i.e. evidence that gluco-
neogenesis is generally increased in tumour-bearing organisms. 
Hyperlactataemia has not been observed, however. Normo-
glycaemia found in weight-losing cancer patients suggests 
that the rate of glucose utilization may accommodate the 
increased supply. 
Waterhouse and Kemperman (31) found a limited adaptation of 
cancer patients to glucose administration, but the patients 
tended to show increased fatty acid oxidation even after 
glucose infusion. The "hosts", therefore, were apparently 
in a continual state of energy "deficiency" i.e. mimicking 
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fasting state conditions. This would be the case if the 
tumour was utilizing much of the carbohydrate produced in 
the host. 
Gold's proposal of a systemic energy-~osing cycle is attrac-
tive and theoretically likely. Grubbs et al (36) have tested 
this proposal and shown in rats bearing the Morris hepatoma 
7777, that inhibition of gluconeogenesis with concomitant 
maintenance of high blood glucose levels resulted in mainten-
ance of host body weight and increased nitrogen retention. 
Cancer patients have an increased daily energy expenditure 
and resting metabolic rate, wh en compared with controls (8, 
37), although this was not universally observed (38). A 
greater energy demand on the host may produce an increased 
resting metabolic rate if this were to incorporate an in-
herently increas e d rate of gluconeogenesis. The overall 
failure of a tumour-bearing host to adapt to semi-starvation 
may also be limited to a gluconeogenic increas e in the host 
(5,10,31,37). Bland et al (39) proposed that inefficient 
substrate utilization, of the host, in the presence of an 
adequate dietary intake, may contribute to a cachectic con-
dition , in cancer patients. 
Young (38) has challenged the proposal that increased Cori 
cycle activity could impose an energy "drain" on the host. 
He calculates that if only 15% of t~e lactate produced is 
oxidised, the energy produced would balance the energy loss 
if the remaining 85% of the lactate were recycled to glucose. 
This argument, however, begs the question of the net energy 
cost of these processes. 
The postulation of chemical mediators produced by various 
tumours cannot be ignored. Effects of tumours, independent 
of anatomical alterations may occur at sites remote from the 
site of tumour involvement. Costa (4) has proposed that 
the destruction of normal cells by neoplastic cells may be 
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due to the production, by the former, of chemically definable 
toxic mediators, active in the immediate vicinity of the 
tumour or at distant sites. 
Greenstein (1943)(40), in work on the -liver catalase activity 
of tumour-bearing anfumals, found decreased enzyme activity 
in rats and mice bearing rapidly growing tumours. This effect 
was reversed by tumour removal. He proposed that the tumours 
liberated toxic substances into the blood stream or alternately 
that they removed components from the blood stream of the hos t , 
to cause the inhibition of liv e r catalase. 
Toporek in 1973 (41) investigated the effects of whole blood 
and also the albumin fraction from tumour-bearing rats, on 
liver protein synth esis. Th e whole blood significantly dec-
reased serum prote in synthe s i s , as did the broad albumin 
fraction. The albumin frac t i on in addition caused a d e e-
rease in liver prote in synthe s is . Th e whole blood and 
albumin fractions from thes e Va lker 256-induc ed rats may 
thus have containe d some kind of "signal factor(s)". 
As mentioned briefly in the s ec tion on protein synthesis in 
the tumour-bearing host, "to xo::-i ormone" produced from purified 
extracts of Walker 256 tumours (12) caused marked inhibition 
of the in vitro incorporation of fH}lysine into protein in 
isolated rat diaphragms, both when injected into the animal 
prior to the assay and when it was added to the incubation 
medium of control diaphragms. A fraction was isolated com-
prising two components of the same molecular size as the 
active 11 toxohormone 11 preparation of other workers. 
Ectopic hormone secretion by various histologic types of 
lung carcinoma has been investigated by Gropp et al (42). 
The fact that some tumours are known to secrete various 
small peptides which themselves cause or induce the host 
to elicit inappropriate secretions of hormones, e.g. ACTH, 
HCG, calcitonin, etc., points to the possibility that 
16 
various humoral factors may be released by tu~ours of various 
kinds. 
The proposal of a lipolytic factor in serum from tumour-
bearing hosts has not been substantiat~d (25). Costa and 
Holland (24) proposed that a lipolytic factor caused increased 
fat loss in Swiss-mice bearing Krebs-2 carcinoma. but provide 
no conclusive evidenc~ and their attempts to fractionate their 
tumour suspensions were also inconclusive. 
Mays (22) investigated the lipid-mobilizing activity of serum 
from cancer patients but found no evidence for any fat-
mobilizing substance. Carter et al (29) in 1975, using 
serum from breast cancer patients added to incubations of 
control rat epididym al fat pads, failed to show an increased 
lipolytic rate, nor was there any evidence for a lipolytic 
factor. 
If the increased fatty acid o x ida tion in tumour-bearing hosts 
were mer ely a normal host response to an energy-deficient 
system (as proposed by an increased Cori cycle activity), 
then the likelihood of a lipolytic factor being produced by 
the tumour would be slight. 
Theologides (43) has proposed a mechanism for cachexia in 
cancer patients which depends on the induction of a chaotic 
metabolic state in the host. He proposed that tumours 
could produce (unspecified) allosterically-active metabol-
ites, as a result of the derepression of various genomes, 
which would then be capable of modifying and controlling 
various host enzyme activities. The alleged allosteric 
metabolites may induce a chaotic metabolic state by sense-
less activation and inactivation of enzymes. This would 
disturb metabolic patterns in the host and subvent metabolic 
equilibrium; tumours would be able to trap any nutrients 
released by these reactions. The primitive nature of the 
tumour cell would render it less vulnerable to the effects 
of the peptides it may produce. 
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This idea is attractive in view of the specific patterns of 
enzyme regulation observed in cancer patients (15). Schein 
et al (10) haveproposed that release of a metabolic toxin 
by the tumour may be responsible for the failure of the host 
to adapt to "fed" conditions, i.e. to _regulate fatty acid 
oxidation accordingly. It is possible, however, that 
removal of tumours does not remove the source of a "toxin" 
but that it removes the glycol y tic "machine" proposed by 
Gold, reducing Cori cycle activity and restoring glucose 
homeostasis to the overall pattern found in normal adapta-
tion to starvation and refeedi n g. 
Cachexia of cancer patients probably arises through a metab-
olic interplay of tumour "ectopic factor" production and 
energy wasting metabolism and may even vary mechanistically 
in the case of different tumours. The most striking 
example of cachexia induced by a tumour ha s b een provided 
by Strain et al (9), who found significant weight loss in 
mice bearing a xenografted hyp e rnephroma from a weight-
losing can c er patient. The t um our, therefore, not only 
caused weight loss in the human host (up to 30 kg in the 
two months prior to surgery) bu t also caused weight loss 
(>25%) in immunosuppressed mic e , when the tumour comprised 
only 5% of the host body weigh t . 
Tumours may thus produce "ectopic factors" that can act 
across species barriers or they may, by their metabolism, 
cause metabolic "chaos" in any host type, by the preferen-
tial sequestration of fuel nutrients and by inefficient 
energy-producing system~. 
1. 3. OUTLINE OF RESE·ARCH UNDERTAKEN. 
The Mork that will be presented in the next chapters was 
undertaken to investigate various important areas that 
appear lacking so far in studies . conducted on the cachexia 
of cancer patients. 
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Initially work was done to evaluate the frequency of weight 
loss in a spectrum of tumour types. No reports of any 
epidemiologic studies of mass loss in cancer patients could 
be located. Using anthropometry, data on arm muscle areas 
and arm fat areas of control non-cancer patients (n = 258) 
were obtained in order to define tissue losses in a series 
of fifty-two cancer patients bearing a variety pf tumour 
types. 
In vivo studies on arm muscle proteolysis in human subjects 
were then undertaken to investigate the status of muscle 
protein metabolism in situ. Arterio-venous amino acid 
differences were accordingly measured across the forearms 
of a group of weight-losing cancer patients; a group ·of 
non-cancer weight-losing patients and a group of non-weight-
losing patients served as controls. 
The rates of net proteolysis and lipolysis in rat muscle and 
adiposetissue respectively were measured to determine whether 
serum from weight-losing cancer patients would elicit a cata-
bolic state in vitro; a positive result would enable the 
demonstration that the serum of cancer patients contained a 
proteolytic or lipolytic factor that metabolically contributes 
to the cachectic state developing in those patients. 
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CHAPTER 2 
AN · ANTHROPOMETRIC STUbY OF MUSCLE AND FAT WASTING IN 
PATIENTS SUFFERING FROM CANCER 
2.1, INTRODUCTION 
As reviewed in Chapter 1, cachexia of cancer patients is a 
vital criterion in the ultimate survival of the patient, and 
appears to have no correlation with calorie intake, tumour 
burden, tumour cell type or anatomical site of involvement 
(4,6,7,44). Breast cancer patients, however, seem to have 
a particularly low occurrence of weight loss. 
An anthropometric study was t hus undertaken, to determine 
muscle and fat areas in 52 cancer patients and 258 control 
patients suffering from minor , non-cancer, conditions, in 
order to assess t he d egree of cach exia in pa t i ent s with 
cancer. Ant hropometry is an a ccepted means of sho wing 
protein-calorie undernutrition and is easily appli e d to clini-
cal use (45,46,47,48,49 , 50,51,52,53,54). Th e cancer patients 
studied formed predominantly two groups: patients having 
breast cancer and patients having other types of cancer. The 
series of other patients suffering from minor conditions was 
studied to derive standard data for both sexes and for white 
and black individuals, respectively. Fat area and muscle 
area values for all the patients were then calculated and the 
cancer patients compared with controls on the basis of mean 
standard values appropriate for their sex and racial group . 
2.2. MATERIALS ANDMETHODS 
2.2.1. Selection of Cancer Patients. 
Twenty breast cancer patients (10 patients in remission, 
10 with progressive disease), 17 lung cancer patients, 5 
cervical cancer patients and a mixed group of eight patients 
having other tumour types, including hepatoma, lymphoma and 
20 
carcinoma of the bladder, anus and post-nasal space, were 
studied (total 52). Only twelve of the patients were on 
treatment, none were receiving hormones, none were diabetic, 
and patients with tumours of the ore-pharynx or gastro-
intestinal tract were excluded. All · patients were ambula-
tory and were graded 1-10 according to performance status 
(55). 
2.2.2. Anthrop-0metric Measurements. 
All anthropometric measurements were taken by one person to 
eliminate inter-Jbservation error (47,50,56). The measure-
ments taken were the upper mid-arm circumference and triceps 
skinfold thickness, according to the method described by Jel-
liffe (45) A measurement of the triceps skinfold . thickness 
(TST) assesses the patient's available fat reserve, while the 
upper midarm muscle circumfere nce (MAC) is an indicator of lean 
body mass or muscle tissue (45,48,57). In each case the non-
dominant arm was measured (47,56). Women with cancer of the 
left breast, who were right-handed, were excluded as lymph-
atic obstruction resulting from tumour spread or treatment 
could have affected the M.A.C. and T.S.T. measurements in 
these patients. 
Triceps Skinfold Thickness (T.S.T.) 
The triceps skinfold thickness was measured at the midpoint 
on the upper arm, between the acromial process of the 
scapula and the olecranon process of the elbow. In each 
case, the upper arm was held parallel to the body in a 
relaxed manner, while the forearm was supported at the 
abdomen by the arm not being measured. The measurement 
was taken at the back of the arm, by pinching the skin at 
the midpoint and applying a Ponderax Mark II skinfold cali-
per, this being an accepted caliper for use in such studies 
(47,58). 
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Upper Mid-arm C±rcumference (M.A.C.) 
The upper mid-arm circumference was measured at the midpoint 
described above, using a non-stretchable tape measure. 
Calculation of fat area and muscle area from tremeasurements 
of M.A.C. and T.S.~. 
Arm muscle area (M) and arm fat area (F), which are more 
precise indices of body muscle and fat than M.A.C. and T.S.T. 
(46,50,56), were derived using the following formulas: 




M = . . . . . . . . . . . . . . . . . . . . . . . ( b) 
4'1T 
wh ere C = M.A.C. 
T = T.S.T. 
2.2.J. Mean Standard Values o f Fat Area (F) and Muscle 
Area (M) 
(a) Normal white patients: 
Accepted standard values for adult upper mid-arm cir-
cumference and triceps skinfold thickness (45) were 
modified using the equations for (M) and (F), set out 
above, to yield standard (M) and (F) values. Although 
these standard values were those of an American popula-
tion, there was no difference between these values and 
those obtained for twenty normal white South Africans. 
(b) Normal black patients (mixed race or "coloured"): 
The standard values referred to above (45) were found 
to differ from those of black South African persons, 
and therefore mean standard (M) and (F) values for 
adult black males and females were determined separately. 
Accordingly, two hundred and thirty-eight black men and 
women who attended a general out-patient clinic at 
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Groote Schuur Hospital for minor, non-endocrionological 
illnesses were assessed for mid-arm circumference and 
triceps skinfold thickness. There were 118 females 
(mean age 49,7 ± 1,4 years (mean± S.E.) years, and 
120 males (mean age 49,7 ± 1,3 years). The (M) and 
(F) values obtained from cancer patients were then 
expressed as a percentage of the relevant standard 
mean. 
2.3. RESULTS 
There was no difference in tumour load when comparing 
breast cancer patients with patients with other types 
of tumour (see Table 2.1). The muscle and fat area 
measurements of patients suffering from cancers, other 
than those of the breast, showed the presence of wasting 
when they were compared to matched standard values and 
expressed as a percentage of the mean standard value. 
The patients with breast cancer were significantly 
different in these respects (Fig. 2.1). They yielded 
(M) and (F) values that were greater by 10-20% than 
those of a matched standard group. The increase in fat 
area was particularly noticeable. Thus the breast 
cancer patients had 30% more muscle area and 70% more 
fat area when compared with the other cancer patients. 
It is also interesting that there was no significant 
difference between (M) and (F) values in breast cancer 
patients with progressive disease when compared with 
patients in remission, although patients in the former 
group had slightly increased (M) and (F) values compared 
with those in the latter (Fig. 2.2). 
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TABLE 2.1. 
TO COMPARE TUMOUR LOAD ·IN BREAST ~ANGER PATIENTS AND 
PATIENTS WITH OTHER TYPES OF CANCER 
Grade 1 2 3 
Breast Cancer 0 5 5 
Other Cancer 4 19 7 
The tumour load was arbitrarily assessed in the 
following way: Grade 1 = local disease< 3 cm; 
Grade 2 = local disease> 3 cm; Grade 3 = 
metastatic disease. 
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Figure 2.2. Muscle and fat areas of patients with breast cancer; 
in remission or with progressive disease. 
Results are expressed as the percentage of a standard control mean 
value; the mean ±S.E. for each group is given. 
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2.4. DISCUSSION 
The use of anthropometric measurements as an indicator of 
protein-calorie undernutrition is considered valid by many 
workers, when the measurements are conducted as described 
in this article. The measurement of ·muscle and fat areas, 
as opposed to mid-arm circumference and triceps skinfold 
thickness, is advocated by many (46,48,49,50,56), and 
expressing the overall result as a percentage of a standard 
value is considered to be more appropriate (44,45,47,48,49, 
51). 
The formulae for determining (F) and (M) assume that the 
upper arm is cylindrical, an assumption which may be inac-
curate. In determining (M) there is also no provision 
made for variations in humeral diameter, while in deter-
mining (F) th~re is no adjustment made for variatio~s in 
skin compressibility. However, the validity of the above 
assumptions was examined by Heymsfield et al (49), using 
computerised axial tomography. It was found that by expres-
sing M.A.C. and T.S.T. as muscle areas and fat areas, and 
also by expressing these values as the percentage of a stan-
dard value, there was reasonable agreement between the two 
methods, so that anthropometry is acceptable for clinical 
use. Furthermore, T.S.T. correlates well with body fat, 
as measured by body density (58,59). The choice of an 
appropriate standard group is important and appears to be 
lacking in many anthropometric studies. Expressing each 
value as a percentage of the relevant standard mean allowed 
us to make a direct comparison between cancer patients of 
different sex and race. 
This epidemiological study showed anthropometrically that 
patients without breast cancer had profound loss of fat 
-area, and a less-pronounced loss of muscle area. The fact 
that fat areas were reduced by a greater percentage than 
muscle areas in the non-breast cancer patients is _interest-
i~g,· as fat is a greater source of energy, during starvation, 
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than muscle. This greater decrease in fat areas compared 
with muscle areas, in weight-losing cancer patients, has also 
been documented by other workers (50,59). The breast cancer 
patients, however, did not show reduced muscle or fat areas 
but tended, rather, to show increased. values when compared 
with those of a matched standard population. The finding 
that there was no apparent difference between (M) and (F) 
values in breast cancer patients with progressive disease 
when compared with breast cancer patients in remission runs 
counter to current notions, as well as the findings of De 
Wys et al (6), which pointed to an increase in weight loss 
with an increasing number of anatomic sites involved in the 
tumour progression. However, these observations do not 
exclude the possibility that the patients with progressive 
disease had excessively raised (F) and (M) values at the 
onset of disease and that these values had subsequently 
decreased. Indeed, .the greater increase in (F) values over 
(M) values in breast cancer is interesting in view of the 
strongassociation between dietary fat intake and breast 
cancer incidence (57,60,61,62,63,64). Women who are obese 
are thought to have an increased risk of breast cancer, 
especially in post-menopausal years (64). De Waard et al 
(62,63) have shown this fact to correlate well with their 
proposal of a bimodal age distribution in breast cancer 
incidence. The ability of adipose tissue to function as 
a slow-release depot for lipid-soluble carcinogens has also 
been proposed as a possible cause of the association between 
obesity and breast cancer (65). This study has shown that 
muscle and · fat depl~tion -~ccurs in -~any cancers; this is 
generally independent of the anatomical sites of involvement 
or the extent of the disease, but appears to be very much 
reduced in breast cancer patients. The increased fat area 
seen in those breast cancer patients studied, correlates 




SERUM AMINO ACIDS IN WEIGHT-LOSING PATIENTS WITH CANCER, 
AS WELL AS WEIGHT-LOSING PATIENTS NOT SUFFERING FROM 
CANCER AND NORMAL CONTROLS 
3 .1. INTRODUCTION 
There are numerous potential abnormalities in protein 
metabolism in weight-losing cancer patients, as reviewed 
in Chapter 1, and which could predictably produce a severe 
imbalance in protein metabolic homeostasis. 
A study was undertaken to investigate serum amino acid 
levels in vivo, in 12 weight-losing cancer (CWL) patients, 
8 weight~losing noncancer patients, with active pulmonary 
tuberculosis (TWL) and 9 normal controls, in order to 
ascertain which changes are unique to cancer patients. 
The arterial and venous amino acids across the forearm of 
each patient were measured and the arterio-venous amino 
acid concentration differences determined. Increased 
muscle proteolysis is characterized by a venous excess of 
amino aicds and elevated arterial levels of essential 
branched chain amino acids (66). Conversely, decreased 
proteogenesis, as may occur in protein-calorie malnutrition, 
is characterized by decreased arterio-venous amino acid 
differences and reduced arterial pl~sma levels of essential 
branched chain amino acids (66, 67, 68). 
J.2. MATERIALS AND METHODS 
3.2.1. Patient Selection. 
Approval for this study was obtained from the Hospital 
Ethical Committee, and informed consent was obtained from 
all patients studied. 
Patients with various solid tumours (excluding those of 
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the gastrointestinal tract), who had lost at least 10% body 
weight during the preceding 6 weeks, had received no radio-
therapy, surgery or chemotherapy during this time and had 
no evidence of intestinal obstruction or dysphagia, were 
selected for study. All patients had locally advanced 
disease and there was no clinical evidence of metastatic 
disease, with the exception of one patient with adenocar-
cinema of the lung who had a cerebral metastasis. Seven 
patients had lung cancer (three adenocarcinoma, two oat-cell, 
one squamous-cell and one large-cell carcinoma), three 
patients had stage III earcinoma of the cervix and one 
patient had stage III carcinoma of the ovary. 
In addition, patients with active pulmonary tuberculosis 
who had lost at least 10% body weight during the previous 
6 weeks were selected, as well as "normal" patients who had 
been admitted to hospital for minor surgical procedures, 
such as hernia repair, haemorrhoidectomy and varicose vein 
strippitig\ All control patients were studied pre-operative-
ly and none gave a history of recent weight loss. 
None of the patients studied had diabetes or other endocrine 
abnormalities, nor was there biochemical evidence of hepatic 
or renal dysfunction in any of them. 
In all, 12 CWL patients (8 males, 4 females; average age 
53 + 12 years), 8 TWL patients (5 males, 3 females; 
average age 43 i 12 years) and 9 normal controls (6 males, 
3 females; average age 46 i 14 years) were studied. 
3.2.2. Sample ·Co·llection and Preparation. 
Blood samples were collected after a 12 hour overnight fast. 
Patients in all three groups were ambulatory in a hospital 
environment and blood specimens were obtained early in the 
morning before any physical exertion. Venous blood was 
collected from a large antecubital vein without stasis and 
arterial blood was collected by radial artery puncture from 
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the same arm. The clotted blood was centrifuged immedi-
ately and the serum was deproteinized by treatment with 
sulphosalicylic acid and centrifugation before storage at 
-20°c until analysis. Amino acids were measured by ion-
exchange chromatography, using lithium buffers on a Model 
121-M Beckman Amino Acid Analyser. The experimental error 
was found to be less than 5%. 
3. 2. 3. Stati·stical Eva·luation o·f Data. 
Individual amino acids were compared in the three groups 
by applying a two-tailed Student's T test, while individual 
arterio-venous amino acid differences were compared by 
applying the Mann-Whitney U-test (69) to take into account 
the wide scatter of results in each group. The numbers of 
amino acids in venous excess in each group were compared by 
applying a simple Chi-Bquare test. 
3. 3. RESULTS· 
3.3.1. Arterial Amino Acids. 
Mean values for arterial amino acid levels are shown in 
Table 3.1. 
Branched-chain amino acids: All .branched- chain amino acids 
were present at significantly lower concentrations in the 
arterial blood of CWL patients when compared with TWL 
patients. Although the mean valcies for branched-chain 
amino acids were lower in the CWL patients when compared 
with normal controls, these differences were not statistic-
ally significant. 
Gluconeogenic ·amino ac·ids:· The gluconeogenic amino acids, 
serine and alanine, were also present at significantly lower 
concentrations ·in the CWL patients when compared with TWL 
patients. However, in the case of alanine (which is 
thought to be one of the most important ~uconeogenic amino 
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TABLE 3.1. 
ARTERIAL AMINO ACID LEVELS 
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50. 3±6. 2 




219. 2±13. 5 
69. 3±4-1 
37.9+2.8 
72. 5±13. 6 
55.4+3.9 
85.1±8.0 
405. 0±30. 3 
105.0±6. 2 
t Significant difference compared with TB group (TWL). 
* Significant difference compared with control group. 
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acids) this difference was brought about by the stgnificantly 
raised alanine levels in TWL patients when compared with 
normal controls (294 ± 19.5 vs 227.9 ± 23.4, p < 0.05). 
There was no decrease in gluconeogenic amino acids in CWL 
patients compared with normal controls. 
Glycine: One of the hallmarks of chronic malnutrition is 
an elevation of plasma glycine. Neither the CWL nor TWL 
patients had glycine concentrations which differed signi-
ficantly from those of the normal control group. However, 
glycine values were higher in the TWL group compared with 
CWL patients, the difference being marginally significant 
(p < 0.06). 
Ci trulline and o-rni thine:· Ci trulline concentrations were 
significantly decreased in the CWL patients when compared 
with TWL patients (14.7 ± 1.4 vs 24.1 ± 4.3, p < 0.01) and 
contr'ol patients (14.7 ± 1.4 vs 28.3 ± 3.8, p < 0.01), 
whereas there were no differences in this respect between 
TWL patients and controls. 
Arterial ornithine concentrations were very high in TWL 
patients when compared with cancer patients (167.1 ± 8.6 
vs 106.1 ± 16.1, p < 0.01) and controls (167.1 ± 8.6 vs 
72.5 ± 13.6, p < 0.0001), while there was no difference 
in ornithine values comparing CWL patients with normal 
controls. 
3.3.2. Arteri·o-Venous Differences of Amino Acids. 
The means of arterio-venous differences for individual amino 
acids in the three groups of patients are shown in Table 3.2. 
Qualitative assessment of the data showed a significantly 
increased release of the branched-chain amino acids leucine 
and isoleucine from forearm muscles in CWL patients, compared 
with normal controls. Although there appeared to be other 
amino acids with increased venous excess in CWL patients, 
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TABLE 3.2 
AMINO ACID ARTERIO-VENOUS DIFFERENCES 





















Glutamine & Glutamic 
Acid 
Asparagine & Aspartic 
Acid 
CANCER 
µmol / R. 
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+ 38. 7.±31. 9 
+3.8 _±7.5 
* Significant difference compared with Control Group. 
The wide scatter of data accounts fo~ the large standard 
errors of the means. Nevertheless, there is a significant 
venous excess for the 2 essential branched chain amino acids 
leucine and isoleucine in cancer patients compared with normal 
controls. 
Minus sign denotes venous excess; plus sign denotes arterial 
excess. 
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the small numbers of patients studied may have affected 
significance levels. The data were also assessed quan-
titatively by counting the number of amino acids in venous 
excess in each group (Table 3.3). The groups were com-
pared in a 2 x 2 contingency table and a simple Chi-square 
test applied. 
It can be seen from Table 3.3 that there were significantly 
more amino acids in venous excess in the CWL patients when 
compared with TWL patients or normal controls (p < 0.01). 
3. 4. DISCUSS,ION 
Ideally, muscle blood flow should be determined in this type 
of study, as differences in flow may theoretically affect 
the uptake and efflux of amino acids in a muscle group. We 
were unable to make such measurements for a variety of 
practical and ethical reasons and simply endeavoured to 
ensure that patient conditions an~ ambient surroundings 
were as constant as possible for each sampling episode. 
The venous excess of a greater number of amino acids in the 
CWL group implies either 
(i) that there wa~ enhanced proteolysis in the m~scles of 
these patients; 
(ii) that there was reduced proteogenesis without any in-
crease in proteolysis; 
(iii) that blood flow was generally slower in the cancer 
patients; or 
(iv) that the differences arose by chance. 
The finding that venous excesses for leucine and isoleucine 
were signifi,qantly increased in the CWL patients when com-
pared with normal controls does not really help to distin-
guish between these possibilities. During enhanced muscle 
proteolysis resulting from starvation, there is known to 
be an increase in the intracellular pool size of branched-
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TABLE 3. 3 
NUMBER OF AMINO ACIDS IN VENOUS EXCESS 
A.MINO ACIDS IN VENOUS EXCESS 
0-10 11-20 
Cachectic Cancer 4 8 (67%) 
(CWL) 
Cachectic T.B. 6 2 (25%) 
(TWL) 
Normal Controls 7 2 (22%) 
The numbers of patient~ with 0-10 amino acids in venous 
excess appear in the left-hand column, while those with 
11-20 amino acids in venous excess appear in the right-
hand column. 
There are significantly more amino acids in venous excess 
in the CWL group compared with TWL and controls (p < 0.01). 
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chain amino acids which is associated with release of these 
amino acids, leading to elevated arterial levels (70}. 
Likewise, the under-utilization of these amino acids by 
skeletal muscle might also lead to an increased venous 
excess. If there is an under-utilization of amino acids 
in CWL patients, it is unlikely to be wholly on the basis 
of an underlying protein-calorie malnutrition, as in the 
latter situation there is a decreased venous excess of 
amino acids, probably as a result of decreased proteogene-
sis to facilitate protein sparing (71). 
Under-utilization of amino acids might result from decreased 
proteogenesis, which has been demonstrated in skeletal 
muscle of cancer patients (11, 15). Alternatively, prefer-
ential sequestration of certain amino acids by the tumour 
may result in an incomplete complement of amino acids 
presented to skeletal muscle, thereby reducing its capacity 
for proteogenesis. 
Although one would expect an increase in arterial branched-
chain amino acids to occur in patients with an increased 
release of amino acids from muscle, the normal plasma con-
centrations of these substances in the CWL patients may 
have arisen from their enhanced sequestration by the tumour 
itself, or from altered hepatic amino acid metabolism. 
Normal arterial glycine concentrations in CWL and TWL 
patients are consistent with our impression that these 
patients did not suffer from chronic malnutrition. The 
finding of normal glycine values in CWL patients is in 
accordance with the findings of Clarke et al (20}. 
The arterial branched-chain amino acid levels were signi-
ficantly lower in CWL compared with TWL patients. It is 
not possible from these data to assess whether these dif-
ferences were due to a decrease in the concentration of 
branched-chain amino ·acids in CWL patients relative to 
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controls which, however, was not statistically significant. 
Conversely, the differences may have been brought about by 
the increase in these amino acids in TWL patients relative 
to controls, which was also not statistically significant. 
Whatever the case, the data define a distinct difference 
in arterial branched-chain amino acids in weight-losing 
cancer patients compared with weight-losing patients with 
a chronic infectious illness, andthis has not been reported 
before. 
Clarke et al' (20) showed normal plasma concentrations of 
branched-chain amino acids in weight-losing cancer patients, 
whereas malnourished patients had low levels of these amino 
acids. However, their non-cancer malnourished.group had 
anorexia nervosa or previous gastrectomies, which would 
not make t h em strictly comparable with weight-losing cancer 
patients, although the latter did have anorexia as well. 
The comparison made between CWL and TWL patients is more 
meaningful, as neither group was biased regarding excessive 
hypophagia or intestinal malfunction secondary to gastro-
intestinal surgery, both of which could produce distinctive 
metabolic changes in their own right. 
The lower arterial concentrations of serine and alanine in 
the CWL patients when compared with TWL patients was the 
result of an increase of these amino acids in TWL patients, 
alanine being significantly elevated in the TWL group when 
compared with both the CWL patients and with controls. It 
is generally assumed that high arterial concentrations of 
gluconeogenic amino acids reflect decreased hepatic uptake 
of these amino acids and therefore implies decreased 
hepatic priming for gluconeogenesis. Conversely, low 
arterial alanine .levels imply increased hepatic gluconeo-
genesis. This did not, therefore, confirm the findings 
of Clarke et al (20), who found a significant decrease in 
glucoenogenic amino acids in their CWL patients. 
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The only clear-cut difference in arterial amino acid con-
centrations between CWL and all other patients was the 
significant hypocitrullinaemia. Citrulline is an inter-
mediate in the urea cycle, and hypocitrullinaemia may 
reflect a block in synthesis, since ornithine levels were 
normal. 
These data therefore suggest enhanced muscle proteolysis 
or decreased utilization of amino acids by muscle in CWL 
patients. Lower arterial amino acid levels in CWL patients 
may be accounted for by tumour sequestration of these amino 
acids or by altered hepatic metabolism of amino acids. 
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CHAPTER 4 
HAS SERUM FROM CACHEGTIG CANCER PATIENTS A PROTEOLYTIC EFFECT 
ON MUSCLE? USE OF HETEROLOGOUS IN VITRO ASSAY SYSTEMS 
4.1. INTRODUCTION 
The cachectic condition of some cancer patients has led to 
the proposal of a tumour-produced ectopic factor(s) which 
could stimulate muscle proteolysis and thus cause increased 
loss of lean body mass (ref. Chapter 1). Alternately, the 
tumour may prov9ke a host response which might give rise to 
the cachectic condition (ref. Chapter 1). This idea was 
investigated in the work being reported in this chapter. 
Heterologous in vitro assays o f skeletal muscle proteolysis 
were established in order to d e termine what influence, if 
any, serum from cachectic can c er patients might have on 
proteolysis in muscle and if this influence could contribute 
to the cachectic condition. 
Investigations of muscle protein degradation have been 
limited by methodological difficulties. Intact animal sys-
tems are prone to a variety of difficulties and possible 
artefacts (72), monitoring degradation by measuring the 
disappearance of radioactively labelled proteins. In con-
trast, isolated mammalian muscles incubated in vitro permit 
controlled investigations of muscle protein metabolism. 
Isolated rat diaphragms have many advantages that are attri-
buted to their rapid dissection and preparation; the thin 
(often translucent) nature of the sheet of muscle fibres 
(73, 74), and because quarter diaphragms isolated from one 
animal (allowing direct comparisons to be made) provide 
obvious advantages for statistical analysis of complex 
biological variables (73, 75). The measurement of tri-
chloroacetic acid (TCA)-soluble tyrosine, released into the 
medium from the isolated diaphragms, provides a simple and 
reproducible determination of net protein degradation in the 
system (73). 
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In this work, two proteolysis systems were used: the well-
established rat diaphragm system (73,76,77,78,79) and a 
cell culture system using an established myobla s t cell line, 
18, originally isolated from rat skeletal muscle. 
Day-to-day variations between experimental animals (73) 
present a very significant problem in the isolated tissue 
system. To permit a valid comparison of results obtained 
using different rats, results were expressed as a series 
of percentage differences in respect of tissue fragments 
from single animals. Because of the short incubation 
periods for · which the diaphragm assay is suited, and the 
necessity to desalt the serum samples to remove high tyro-
sine blanks, the second in vitro system was tested in a 
similar manner to the tissue s y stem. The 18 skeletal 
muscle cell line has been well-characterized (80). 
4.2. TISSUE INCUBATIONS 
4.2.1. Experimental Procedures. 
(Note: See Appendix for the suppliers of important 
materials used). 
4.2.1.1. Preparation and incubation of rat quarter diaphragms. 
Male rats of between 60 - 90 g were sacrificed by cervical 
dislocation and the diaphragms removed and rinsed in ice-cold 
Krebs Ringer Bicarbonate (KRB) buffer (0.12 M NaCl; 0.005 M 
KCl; 0.001 M CaC1 2 ; 0.001 M Mgso 4 
x 7H20; 0.001 M KH 2Po 4 ; 
0.025 M NaHC0
3
; pH 7.4 equilibrated with 95% o2 - 5% CO 2 ). 
The central tendon and ribs were carefully dissected away 
and each hemidiaphragm bisected parallel to the muscle fibres 
to yield four diaphragm pieces. The pieces were weighed and 
placed into 25 ml Erhlenmayer flasks containing 2 ml KRB-
buffer, equilibrated with 95% o 2 - 5% CO 2 , and preincubated 
for 30 mins at 37°C, with shaking. A 30-minute preincubation 
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is recommended (75) to allow resealing of damaged muscle 
fibres. 
The muscle ~ieces were then transferred to incubation flasks 
containing 2 ml incubation medium, equilibrated with 95% o2 -
5% CO 2 and incubated for 3 hours (unless otherwise stated), 
at 37°c with shaking. The incubation medium contained 
60 µg/ml penicillin G and 100 µg/ml streptomycin sulphate 
during every incubation period lasting 3 hours. After 
incubation, the muscle tissue was removed and usually dis-
carded, except for the determination of the intracellular 
muscle pools of tyrosine, when the muscle was rinsed, blotted 
and homogenized in 1 ml cold 10 mM potassium phosphate buffer, 
pH 7.4, using an Ultraturrax homogenizer (Janke & Kunkel, 
FRG). The protein was precipitated by adding an equal value 
of 20% TCA, keeping the mixture on ice for 30 mins and then 
centrifuging for 30 mins at 2 000 g, at o0 c in a Beckman 
TJ-6R centrifuge. 
The incubation medium was routinely collected and the TCA-
soluble supernatant prepared (as described above). The 
tyrosine content of the TCA-soluble fraction of the medium 
(or muscle homogenate) was determined fluorometrically by 
the method of Waalkes and Udenfriend (74) which is sensitive 
and specific for tyrosine, either in the free form or in 
oligopeptides. In incubations where an "antiproteolytic" 
mixture of agents (insulin, 0.1 units/ml; glucose, 10 mM; 
branched chain amino acids (BCA), 5 x normal rat plasma 
concentrations (80), or hormones such as hydrocortisone 
(in amounts varying from 50 mg to 5.0 mg) and glucagon 
(varying from 50 pg to 500 µg) was added, these were added 
to both the preincubation and incubation media. Incubations 
performed in 50% serum or cell culture medium were preincubated 
in KRB-buffer alone. 
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4.2.1.2. Tyrosine determinat i on 
To 2 ml of acid supernatant we re added 1 ml l-nitroso-2-
naphthal reagent and 1 ml nitric acid reagent; the tubes 
were stoppered, shaken well and incubated at 55°c for thirty 
minutes. After coolino-, 9 ml 1, 2-dichloroethane was added, 
0 
the tubes again shaken and s p un at 700 g, briefly, to 
separate the organic phases. The unchanged nitrosonaphthal 
reagent was extracted into t he organic phase, and discarded. 
The upper aqueous phase, conta ining the nitrosonaphthal 
tyrosine derivative, was remo v ed and assayed in a Perkin-
Elmer fluorescence spectropho t ometer (Aex: 460 nm; Aem: 
570 nm). The tyrosine content of samples was determined 
by reference to a standard curve obtained for free 1-tyrosine, 
and the rate of tissue proteolysis was finally expressed as 
the net release of tyrosine p e r mg wet muscle weight per hour. 
4.2.1.3. Selection·, preparation and incubation of patient 
serum samp-les. 
Cancer patients who were not undergoing treatment, who had 
normal liver functions and were not diabetic nor suffering 
from other obvious endocrinological disorders, were selected 
for this study. Five such patients having substantial 
weight loss within the six months preceding the blood sampling 
and bearing a variety of mali gnant tumours (including lung and 
cervical carcinomas, but excluding any ore-pharyngeal or 
gastro-intestinal obstructions) were chosen as the weight-
losing cancer patient group. As a non-weight losing cancer 
patient group, 5 patients with progressive cancer of the 
breast were chosen, prior to mastectomy or any other form of 
treatment. 
For each cancer patient selected, there was a sex-, age- and 
race-matched control patient (not suffering from cancer), 
selected. Paired internal co mparisons of effects, on muscle 
proteolysis in vitro, of serum from cancer and matched control 








Blood samples were obtained from patients in the fed state; 
all had given their informed consent. The blood samples 
were c entrifuged at 1000 gin the cold, for 20 mins, and 
the serum was then desalted on a Sephadex G-25 column, 
equilibrated with 0.9% NaCl. The desalting procedure was 
necessary in order to reduce the high background levels of 
tyrosine present in the serum. The incubation medium was 
comprised of equal volumes of serum and double-strength KRB-
buffer. The tyrosine content of the incubation flask, with-
out muscle, was determined for each serum sample. This 
tyrosine "blank" was then subtracted from each respective 
experimental tyrosine value to give a "corrected". tyrosine 
release value. The tyrosine "blank" of desalted serum was 
less than 5% of that released by the tissues. 
4.2.1.4. Treatment of r~ts. 
Adult male rats of approximately 400 g body weight were sub-
jected to various treatments in order to impose physiological 
modulations in vivo; the serum of such rats was tested as a 
"model" for the experiment~ conducted with human sera, i.e. 
the response of the target diaphragm pieces to serum of vary-
ing "proteolysis promoting" potential could be assessed. 
Two rats were subjected to each of the following treatments: 
Fasting (rats maintained on water alone for 90 hrs or 130 
hrs); induced diabetes mellitus (rats treated with a dose 
of 8 mg Alloxan/100 g body weight (83) and sacrificed on Day 
5 after injection); Hypercortisolism (rats treated with 
hydrocortisone sodium succinate at 5 mg/100 g body weight/ 
day for 5 days, and were either fed or fasted for 130 hr, 
being sacrificed 24 hrs after the last injection), and Hyper-
thyroidism (rats injected intraperitoneally with 25 µg, 
L-Triiodothyronine (T
3
) per day per 100 g body weight, for 
a period of 17 days, being sacrificed on Day 18 (78,82)). 
The carotid artery of each serum donor rat was carefully, 








with Sagatex. Blood was drained into collecting tubes 
(about 10 mls), allowed to clo t and centrifuged to obtain 
the serum. The serum for each treatment was pooled and 
then desalted and incubated as described (4.2.1.3). The 
effect of serum from the treated rats - was directly compared 
in internal paired comparisons with serum from a fed control 
rat. 
4. 2 .1. 5. Medi um ·from transformed cell cultures. 
R9c110T cells are spontaneousl y transformed cells which have 
arisen from an R
9
c1 10 cell line, derived from neonatal rat 
hearts in the 16th passage. The transformed cells were 
characterized as such by the following criteria: they showed 
anchorage independence on soft agar plates; they had lost the 
capacity to lay down elastin a nd collagen matrices; they 
secreted very high rates of plasminogen activator; their 
rates of cell division were a t least twice those of the R
9
c1 10 
cells; their morphology was altered from that of longitudinal 
rod-like cells, to small spherical cells; and cells from 
R
9
c1 10T cultures, when injected subcutaneously into immuno-
suppressed rats, developed into local fibrosarcomas, on two 
occasions of testing. 
Medium (lacking serum) from t h ese cell cultures was supplied 
by Dr T. Scott-Burden, after it had been exposed to the cells 
for three days. Desalting, and subsequent incubation, 
procedures were as described previously (4.2.1.3.). 
4. 2. 2. Results. 
4.2.2.1. Optimalization of the assay. 
Rat diaphragm quarters incubated in KRB-buffer, preceded by 
a thirty-minute preincubation period, released tyrosine into 
the medium at a linear rate for three hours, both when quarter 
diaphragms from one experimental animal were incubated for 
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Figure 4.1. Release of tyrosine from quarter diaphragm 
pieces of one experimental animal, with time 
of incubation. 
Quarter diaphragm pieces incubated in KRB-buffer for 
0.5 hr, 1 hr, 2 hrs, 3 hrs. Each point repre-
sents the tyrosine released by a quarter diaphragm taken 
from a single experimental animal. 
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tyrosine release was plotted a s the (mean± S.E.) of 3-5 
rats for each time point (Fi gure 4.2). Determining the 
mean values for each time point incorporates day-to-day 
variation between experimental animals; however, the mean 
rate of proteolysis, 0.22 ± 0. 0 4 (mean i S.D.) nmoles of 
tyrosine released per mg wet tissue weight per hour, is 
comparable with literature va l u e s (73). The release of 
tyrosine into the medium was n o t the result of a non-specific 
leakage of material from the i n tracellular pools (Figure 4.3). 
The intracellular pool of tyros ine remained constant during 
three hours of incubation; t h e overall slower rate of proteo-
lysis was due to the presence of inhibiting factors (see 
below). The isolated diaphragm may leak intracellular com-
ponents during the first half i our after t he ribs are trimmed 
away, bu t subsequently appears stable by several criteria 
(75) (and hence a 30 min preincubation was routinely performed). 
The net production of tyrosin e was taken to indicate net 
protein breakdown since tyrosine is neither synthesized nor 
degraded in muscle tissue (73); the tissue tyrosine content 
is unch anged over 3 hr of incu oation (suggesting a specific 
release of tyrosine from the intracellular pools) (73), and 
since tyrosine rapidly equili brates between intracellular 
pools and the medium. 
Reutilization of amino acids from the intracellular pools 
occurring concurrently with t he ir release into the medium is 
an important conside r ation in p rotein degradation studies. 
Inhibiting protein synthesis allows absolute rates of proteo-
lysis to be obtained. Cycloheximide, an inhibitor of protein 
synthesis, did not substantially affect the proteolytic rate 
in this investigation (Table 4.1), suggesting that reutiliza-
tion of tyrosine during 3 hour incubation is minimal. Cyclo-
heximide has been known to reduce absolute rates of protein 
degradation concomitantly with inhibition of protein synthesis 
(73). For purposes of this s t udy, where absolute rates of 





















Figure 4.2. Mean release of tyrosine with time of incuba-
tion of 3-5 experimental animals. 
Release of trichloracetic acid (TCA) soluble tyrosine 
from muscle protein at different times of incubation, 
where each point excluding 30 mins incubation is the 
mean ±S.E. for muscle pieces from between 3-5 rats. 
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Figure 4.3. The intracellular pool of tyrosine over 
three hours in incubation. 
Release of TCA-soluble tyrosine from muscle protein 
over 3 hours of incubation, following a 30 min pre-
incubation period, in KRB-buffer + insulin (0,1 units/ 
ml) glucose (10 mM) branched chain amino acids (x5 
plasma concentration). 
Tyrosine in the intracellular pool was measured after 









+ 0.5 mM cycloheximide 
(Mean_:!: S.D.) 
Net Tyrosine Release 
(nmoles/mg/hr) 
0. 31 + 0. 01 
0. 32 + 0. 02 
Results are the (mean_:!: S.D.) for paired duplicate 
samples within one experimental animal. The 
percentage variation is 3%. 
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measured and overall rate of proteolysis determined, in the 
face of ongoing protein synthesis. 
Tyrosine release determined fluorimetrically was exactly 
reproducible (Figure 4.4) and ga ve experimental values that 
were 30-40% higher than those f or the same experimental 
samples given by amino acid ana lysis (Table 4.2); the 
fluorimetric procedure also mea sures small tyrosyl-peptides 
in the TCA-soluble fraction of the precipitated medium. In 
the course of this report, all tyrosine release data include 
these small acid-soluble peptides. 
The system responded to various physiological stimuli. Fasted 
rat diaph ragms released more t y rosine than diaphragms from fed 
rats (Fi gure 4.5). It was hoped that diaph ra gm s from fasted 
rats may have released suffici ent tyrosine to accommodate the 
tyrosine blank of serum and allow addition of ''whole" serum 
to the inctibation flasks. Un f ortunately, this was not the 
case. 
Addition of factors known to inh ibit . tyrosine release from 
isolated diaphragms gave a decr ease of 31 ± 0.9% (mean± S.E.) 
in the proteolytic rates of isolated diaphragm quarters from 
5 different rats (Figure 4.6). This effect was higher than 
that reported for the influence of each separate agent, i.e. 
insulin 0.1 units/ml; glucose, 10 mM; branche d chain amino 
acids (BCA), 5 times normal ra t plasma concentrations) (73) 
and may have represented additive effects. 
Fed rat diaphragms were routinely used in the investigations 
on serum from cancer patients, since diaphragms from fasted 
rats, in a proteolytic mode, would require any proteolytic 
factor present in the serum to enhance already "activated" 
processes. 
Known promoters of catabolism present in serum in varying 
amounts, which could be responsible for altered proteolytic 
bo 
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Standard curve for the determination 
of tyrosine. 
The range of 0-20 nmoles tyrosine was measured fluorimet-
rically (Aex: 460 nm; A em: 570 nm). Each point is the 
mean ±S.D. of 20 determinations. 
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TABLE 4.2 














nrnoles Tyrosine using 






TCA-soluble tyrosine released into KRB-buffer or KRB-buffer + 
insulin (0.1 units/ml); glucose 10 mM; branched chain amino 
acids, 5 x normal rat plasma concentrations, during 3 hr 
incubation periods. 
Amino acid analysis measured using lithium buffers, and a 
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Figure 4.5. Tyrosine release from diaphragms of fed . or 
fasted rats. 
TCA-soluble tyrosine released from muscle protein, into 
KRB-buffer, using diaphragms from fasted(!) and fed ( I ), 
during various periods of incubation. Each point, 
excluding 30 mins incubation, is the mean ±S.E. of 
3-5 rats. 
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Figure 4.6. Release of tyrosine into KRB-buffer 
and supplemented KRB-buffer. 
Proteolytic rates of quarter diaphragms from fed 
rats in KRB-buffer alone or in medium supplemented 
with insulin.- 0,1 units/ml; glucose, 10 mM; 
branched chain amino acids (BCA) at 5x normal rat 
plasma concentrations. 
mean ±S.E. for 6 rats. 
Each value represents the 
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rates independently of cancer-specific serum factors, were 
tested in the system to assess the significance of their 
possible contributions. Glucagon and hydrocortisone added 
at concentrations in the human physiological ran ge exerted 
no significant effects on proteolytic rates (Figures 4.7a; 
4.8a); the concentration of glucagon. to 106 times the 
physiological level, caused an increase in proteolysis of 
about 90%; this effect was dose dependent (Figure 4.7b). 
However, the likelihood of such glucagon levels being present 
in serum samples from patients selected by the criteria set 
out (4.2.1.3), is very small and was ignored. 
Supra-physiological amounts of hydrocortisone did not elicit 
any response from the muscle tissue (Figure 4.8b). This 
may not be surprising in view of a finding by Tomas et al 
(76) which indicates that the active hormone in the rat is 
corticosterone. The influence of varying physiological 
levels of either glucagon or hydrocortisone in the serum 
samples, and hence added to the incubation medium, was 
ignored. 
4.2.2.2. Effects of serum from cancer patients. 
Serum from either fed or fasted patients contained, on average, 
50-60 nmoles of tyrosine per ml of serum. This serum tyro-
sine blank was reduced to an acceptable level for experimental 
purposes by desalting on a Sephadex G-25 column, namely about 
2 nmoles/ml tyrosine, which was less than one-tenth the experi-
mental values. 
Serum from human control subjects, incubated in a 1:1 ratio 
with KRB-buffer caused a slight decrease in the release of 
tyrosine from muscle (Table 4.3). The mean percentage dec-
rease was 11 ± 4.4% (mean± S.E.) for paired internal com-
parisons and was hardly above the 5-7% error inherent in the 
system. Serum addition to supplemented medium {i.e. medium 
containing insulin; glucose; BCA) also caused a decrease 
of 20 + 6.3% (mean+ S.E.) for paired internal comparisons. 
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Figure 4.7(a)&(b). Effect of glucagon in (a) physiolo-
gical and (b) supraphysiological amounts on 
the proteolytic rate of isolated rat diaphragms. 
Glucagon added in (a) physiological amounts (50 pg; 100 pg; 
500 pg); (b) supraphysiological amounts [x10 6] (50 µg; 
100 µg; 500 µg). 















Figure 4.8(a) & (b). Effect of hydrocortisone in (a) 
physiological and (b) supraphysiological amounts 
on the rate of proteolysis in isolated rat 
diaphragms. 
Histogram shows duplicate paired comparisons 
samples from individual experimental animals. 
cortisone added in (a) physiological amounts 
and (b) supraphysiological amounts (0,5 mg; 
within tissue 
Hydro-




EFFECT OF CONTROL HUMAN £ERUM ON THE RATE OF TYROSINE 







50% serum .••. 
KRB-buffer .•. 
50 % serum .•.. 
nmoles tyrosine release 
pe~ m.g per hour 
0.21 + 0.04 
0.18 + 0.01 
0.14 + 0.01 
0.11 + 0. 0 3 
Diaphragm pieces incubated in medium containing 50% 
desalted serum from a human control patient, or KRB-
buffer alone and in the presence or absence of insulin, 
0.1 units/ml; glucose, 10 mM; branched chain amino 
acids (BCA) at 5 x normal concentration. Results are 
the mean+ S.D. of 3 rats and serum from 3 control 
patients. 
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This suggests that human serum contains one or more inhibi-
tory factor(s). Incubatioooinvestigating serum from cancer 
patients were routinely performed in unsupplemented medium. 
Comparisons of serum from a control patient whether in a fed 
or fasted state, showed no significant differences in tyrosine 
release (Table 4.4), the slight inhibitory effect of serum 
addition on theoverall rate of proteolysis (normal rate, 0.22 
nmoles/mg/hr) is apparent in both cases. There appeared no 
advantage therefore in using serum from fasted patients, 
hence serum samples were routinely obtained from patients 
who were fed, which in any case could be more closely moni-
tored. 
Serum samples from 5 weight-losing cancer patients were com-
pared, in internal paired experiments with serum samples from 
5 matched control patients. No difference in proteolytic 
rate was observed (Table 4.5). Likewise, serum samples from 
5 non-weight losing cancer patients compared with 5 matched 
control patients also showed no difference in proteolytic 
rate (Table 4.5). Expressing the results as percentage dif-
ferences of paired internal comparisons gave a mean 9% in-
crease in proteolytic rate attributable to serum from weight-
losing cancer patients, and no increase for serum from non-
weight-losing cancer patients (Table 4.6). The 9% increase 
seen was hardly above the 5-7% error inherent in the system. 
4.2.2.3. Effects of transformed ce~ culture medium. 
A continued investigation of any cancer-mediated effect on 
in vitro muscle proteolysis 
the R9c1 10T cell cultures. 
produced by the transformed 
was carried out using medium from 
It was hoped that any factors 
rat cells and secreted into the 
medium would elicit a response in the incubation system, 
and because a rat cell line was used, species differences 
would be eliminated. 
Medium obtained from these cell cultures failed to show any 
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TABLE 4.4. 
TYROSINE RELEASE IN THE PRESENCE OF SERUM FROM ONE CONTROL 
PATIENT IN A FED OR FASTED STATE 
Serum source 
Fed control patient 
Fasted control patient 
n moles Tyrosine release from 
protein/mg/hr 
0.14 + 0.01 
0 .15 + 0. 01 
Serum addition was 50% of the incubation medium. The 
"fasted" serum sample was coll e cted after a 20 hr fast, 
the "fed" serum sample was collected 2! hours post-eating, 
and both samples came from one control patient and were 
used fresh. following desaltin g . 
The results are the mean+ S.D. of an internal paired 
duplicate experiment. 
61 
TABLE 4. 5. 
PROTEOLYTIC RATE OF ISOLATED DIAPHRAGM PIECES IN THE 
PRESENCE OF SERUM FROM WEIGHT-LOSING AND NON-WEIGHT 
LOSING CANCER PATIENTS 
Source of serum 
Weight-losing cancer patients 
Control (non cancer) patients 
Non-weight losing cancer patients 
Control (noncancer) patients 
Incubation in 50% desalted serum. 
Proteolytic rate 
(nmoles/mg/hr) 
0.18 + 0.02 
0.17 + 0.02 
0.19 + 0.03 
0.19 + 0.03 
Internal paired 
comparisons between serum from cancer and matched control 
patients performed using 5 weight-losin g and 5 nonweight-
losing cancer patients. Each determination performed 
in duplicate. 
Results are the mean+ S.D. of 10 animals in each group. 
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TABLE 4. 6 . 
THE PERCENTAGE INCREASE IN PROTEOLYTIC RATE OF INCUBATIONS 
IN THE PRESENCE OF "CANCER" SERUM COMPARED WITH "CONTROL" 
SERUM 
Cancer Patient Group 
Weight-losing ..•••..• 
Non-weight losing •.•. 
% Increase in Proteolytic 
rate 
9 + 11.1 
0 + 5.8 
Expressing the change in prot eo lytic rates as a percentage 
increase for paired duplicat e determinations on single 
experimental animals. Results are the mean+ S.D. 
Percentage increase in proteolytic rates determined indi-
vidually for cancer and control patient serum samples; 
and for both cancer patient groups. The% increase in 
proteolytic rate= 
Proteolytic rate in "cancer'' serum - proteolytic rate in 
"control" serum 
Proteolytic rate in "control" serum 
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effect, either when comparing this medium with KRB-buffer 
(Table 4.7) or when comapring it to the effect obtained 
using medium from untransforme d R
9
c1 10 cell cultures (Table 
4.8). The percentage difference for paired internal com-
parisons was 7% in both cases. 
4.2.2.4. Effects of serum fro m rats. 
The response of the in vitro rat muscle proteolysis system 
was further investigated usin g various rat serum samples 
obtained from rats subjected to a variety of hormonal and 
physiological treatments. The response of rat muscle to 
factors present in rat serum, wa s thus investigated. 
Serum from control fed rats had no significant effect on the 
KRB-buffer system (Table 4.9), the percent difference for 
paired internal comparisons being 3 ± 2.8% (mean± S.E.). 
Addition of serum from rats fasted for 90 hr or 130 hr com-
pared with serum from fed rats, produced no difference in 
the mean proteolytic rates (Ta bl e 4.10). 
A paired internal comparison of the proteolytic rates of rat 
muscle pieces incubated in serum from fed rats with serum 
from diabetes-induced rats and from hydrocortisone-treated 
rats, either in a fed or 130 hr fasted state, showed no 
differences either (Table 4.11). Serum from fed rats com-
pared with serum from T
3
-treated rats showed no significant 
difference (Table 4.12). 
In all these cases the percentage difference of the paired 
internal comparisons showed no variation above the error 
for the system. All the treatments, however, caused in-
creased proteolysis of isolated muscle of the animals i£ vitro 
(78,79,83). Serum from these animals may be expected to 
contain a variety of hormones and other substances, so that 
hcubated diaphragm pieces should reflect their activity, 
in so far as they survive the desalting procedure required 
to prepare the serum. Animals may, however, vary in their 
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TABLE 4. 7. 
TYROSINE RELEASE IN THE PRESENCE OF MEDIUM FROM TRANSFORMED 
CELL GULTURES 
Incubation condition 
KRB- buffer .•. ........... 
1:1 ratio KRB-buffer and 





0.21 + 0.06 -
0.19 + 0.05 
The release of TCA-soluble tyrosine in the presence of 50% 
medium from transformed cells i.e. R
9
c1 10T cell cultures 
compared with the release into KRB -buffer. Results are 
the mean± S.D. of paired duplicate experiments using 
4 rats. 
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TABLE 4. 8 
TYROSINE RELEASE IN THE PRESENCE OF CELL CULTURE MEDIUM 
FROM TRANSFORMED AND UNTRANSFORMED CELL CULTURES 
Source of cell culture medium 
R
9
c1 10 cell cultures ....••••. 
R9c1 10T cell cultures ••.•..•. 
Proteolytic rate 
(nmoles/mg/hr) 
0.19 + 0.09 
0. 21 + 0. 09 
( Mean.± S.D.) 
Quarter diaphragms incubated in the presence of 50% 
medium from transformed cell cultures (R
9
c1 10T) or 
medium from untransformed R
9
c1 10 cell cultures (control). 




TYROSINE RELEASE IN THE PRESENCE OF SERUM FROM FED RATS 
Incubation condition 
KRB-buffer .•••.••..• 
1:1 ratio of serum from 
a fed rat and KRB-buffer 
Proteolytic rate 
~moles tyrosine/mg/hr 
0.27 + 0.04 
0.25 + 0.05 
Quarter diaphragms incubated in the presence of 50% serum 
from a fed control rat and compared with incubation in 
KRB-buffer alone. Results ar e the mean+ S.D. of five 
rats. 
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TABLE 4 .10. 
TYROSINE RELEASE IN THE PRESENCE OF SERUM FROM FED RATS 
AND FASTED RATS 
Nutritional state of serum 
donor rat 
Fed . ..••...••.........••.• 
90-hour fasted ••........•. 
130-hour fasted ..•..•...•. 
Proteolytic rate 
(nmoles/mg/hr) 
0.25 + 0.05 
0.25 + 0.03 
0.25 + 0.03 
Release of tyrosine in the presence of serum from fed 
rats compared with the release in. the presence of serum 
from 90-hour and 130-hour fasted rats. Results are 
the mean± S.D. using 4 separately pooled sets of sera 
and performing each set in duplicate. 
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TABLE 4.11. 
TYROSINE RELEASE IN THE ·PRESE NCE OF SERUM FROM RATS 
SUBJECTED TO VARIOUS PHYSIOLOGICAL STRESSES 









0.23 .± 0.007 
0.24 + 0.02 
0.22 + 0.02 
+ 130-hour starvation...... 0.24 + 0.04 
Quarter diaphragms incubated in the presence of 50% 
serum from rats subjected to various treatments. Each 
serum sample was pooled from 2 rats. Results are the 
mean.± S.D. of duplicate pair ed determinations. 
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TABLE 4.12. 




Treatment of donor rat prior 
to serum collection 






0.26 + 0.02 
0.25 + 0.05 
Quarter diaphragms incubated in the presence of 50% 
serum from T3-treated rats and compared with incubation 
in serum from control rats. Results are the mean+ S.D. 
of duplicate matched internal comparisons. 
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response to the treatment, or a lternately the factors 
produced may be present in dif f erent amounts and may cancel 
out the effects such that overall no variation is seen. No 
prediction can confidently be made of what one would expect 
to find in this type of experi ment. 
The overall lack of response was disturbing since it suggested 
a lack of sensitivity in the s y stem. Alternately, the de-
salting process or insuffici ent length of incubation could 
have contributed or invoked t hi s loss of sensitivity. An 
alternat e proteolysis system was therefore investigated, 
which deviated the problem of incubation time, and desalting 
of the serum: in orde r to confirm the absenc e of proteolysis 
promoting factor(s) in s e rum as tested by th e diaphragm assay. 
4.3. CELL CULTURE ASSAYS 
4.3.1. Experimental Procedur es . 
4.3.1.1. Culture of cells. 
The established myoblast cell line 18, originally isolated 
from rat skeletal muscle (80) was used. 
Cells were thawed from storage in liquid nitrogen and grown 
to confluence in 75 cm 2 stock flasks in a 4:1 mixture of 
Dulbecco 1 s Modified Eagle's Me d ium and Medium 199 containing 
10% horse serum (see Appendix), 60 µg/ml penicillin G and 
100 µg/ml streptomycin sulphat e . Cells were incubated at 
37°c in a humidified incubator with 5% CO2 in air. After 
myoblast proliferation to confluence in the stock flask, the 
cells were dissociated with Trypsin-EDTA solution and seeded 
at 105 cells per 35 mm petri dish containing 2 ml of growth 
medium. The medium was changed every three days. Once 
confluent, the cells progressively fused to form large multi-
nucleate syncytia (myotubes) wh ich synthesized muscle-specific 
proteins and contracted spontane ously after 7-8 days growth. 
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All experiments were performed on cells between sixth and 
tenth passage and were initiated on dishes showing at least 
80% of nuclei in fused myotubes. 
4.3.1.2. Radioactive labelling of cell proteins. 
Cell cultures were labelled for 16 hours in growth medium 
containing 1 µCi/ml of [ 3H]-phenylalanine; this resulted 
in the preferential labelling of proteins having relatively 
long half-lives i.e. 11 long-li ved 11 proteins ( 80). The 
radioactive medium was then removed and the cells were 
washed rapidly in ice-cold sterile phosphate-buffered saline 
(PBS), in order to remove all extracellular [3H]-phenyl-
alanine (4 such washes were sufficient)(80). A series of 
four consecutive 30-minute incubations at 37°c, adding 1 ml 
fresh growth medium after each one, was carried out to 
11 wash out" the intracellular free (3H]-phenylalanine. This 
resulted in a stepwise extraction of the intracellular [3H]-
phenylalanine since it has been shown that the intracellular 
concentration of [3H]-phenylalanine is directly proportional 
to the extracellular concentration after 30 mins at 37°c (80). 
A minimum level of intracellular [3H]-phenylalanine was 
reached which remained constant throughout any subsequent in-
cubations. The release of [3H]-phenylalanine was measured 
as the net increase in acid-soluble radioactivity during in-
o cubations with test media. Following the washes at 37 C, 
1 ml of fresh 11 chase 11 medium containing 1 mM excess non-
labelled phenylalanine was added to the cell layers. The 
excess 11 cold 11 phenylalanine decreased isotope reutilization. 
The release of labelled amino acid into this medium for 
various time periods, was measured to determine the rate of 
intracellular proteolysis: Cells were incubated at 37°C, 
after which the medium was removed and assayed for TCA-soluble 
radioactivity by precipitation with equal volumes of 20% TCA 
for 30 mins at o0 c. The cell layers were washed with PBS 
and 1 ml 1% sodium dodecyl sulphate (SDS) was then ~dded to 
solubilize the cells, which were removed from the culture 
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dish after 10 minutes, using a 
solubilization was repeated. 
then briefly sonicated, a 1 ml 
11 rubber policeman". This 
The SDS lysate (2 ml) was 
aliquot counted to determine 
the total radioactivity within the cells and the remaining 
1 ml was supplemented with 1% bovine serum albumin (acting 
as a carrier), precipitated with equalvolumes of 20% TCA at 
o0 c for 30 mins and then spun at 1200 g for 15 mins using 
a Beckman TJ-6R centrifuge. The supernatant from the cell 
lysate was counted to obtain th e residual amount of intra-
cellular TCA-soluble radioactivity. 
All samples were counted in I n stagel, in a Beckman scintil-
lation counter. The sample s were checked for chemilumines-
cence after 24 hours, but due t o the acidic nature of the 
samples, this was never a si gnificant problem (80). 
Intracellular protein degradation in each case was expressed 
as the percentage of initial to tal protein radioactivity 
t hat was released into the "chase" medium as free amino acid: 
% Proteolysis= dpm ['H]-Phe in TCA-sol. medium, where dpm in 
dpm in Total Protein at time 0 
Total Protein at time O = (To tal intracellular dpm - intra-
cellular TCA-soluble dpm). 
4. 3.1. 3. Intracellular proteolysis in the presence of human 
serum. 
Cells were grown as described and labelled for 16 hours under 
the conditions described for basal proteolysis measurements. 
During the two hour, step-wis e extraction, washing procedure, 
and during the following chas e period, the cell layers were 
incubated in medium containin g 10% human serum (from either 
control, non-cancer bearing patients or from weight-losing 
cancer patients) added in the place of the 10% horse serum. 
Where the percentage human serum substitution was >10% (i.e. 
15% or 40%) the medium was pre sent only during the chase 
period. The proteolysis rate was measured and the results 
· 73 
expressed, as described for basal proteolysis measurements. 
Control human serum samples were obtained from a healthy, 
noncancer-bearing patient, in the fed state (see 4.2.1.3). 
Serum samples were obtained from cancer patients satisfying 
the criteria set out (see 4.2.1.3), and having substantial 
weight loss. No non weight-losing cancer patients were used 
in this study (i.e. patients having cancer of the breast). 
The serum obtained from centrifugation of the blood samples 
was added to the medium following sterile filtration, and did 
not undergo prior desalting as described previously (see 
section 4.2). 
All serum samples were used on the day they were obtained 
from the patients. 
4.3.1.4. Accel·erated intracellular proteolysis. 
Cells were grown as described and labelled for 16 hours as 
for basal proteolysis measurements. As described above, 
during the 2 hour step-wise extraction washing procedures, 
and during the subsequent chase period, the cell layers were 
incubated in a medium which contained no horse serum (or 
human serum substitute) and no chick embryo extract (i.e. 
minimal medium causing nutritional step-down conditions). 
The "accelerated" proteolysis rate was measured as described 
above. 
4.3.1.5. Intracellular proteolysis in the presence of 
inhibiting factors. 
Cells were grown and labelled, as described, and the washing 
procedures were performed as for basal proteolysis. The 
chase medium contained insulin (0.1 units/ml); glucose 
(10 mM) and BCA at five times the plasma concentrations. 
The proteolysis rate in the presence of these factors (known 
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to decrease proteolysis in muscle incubations in vitro (73) 
was then measured. 
4.3.2. Results 
4.3.2.1. Validation of methods. 
[3H]-phenylalanine was chos~n as a marker for proteolysis 
since this amino acid is largely unmetabolized in muscle (80) 
due to the absence of the enz yme phenylalanine hydroxylase. 
Cultures of 18 skeletal muscle cells were used since they 
were a line already in use, and characterized by Dr T. Scott-
Burden and co-workers in this laboratory (unpublished experi-
ments). 
Release of [ 3H)-phenylalanine was linear up to 4 hours, the 
release of radioactive label being expressed as a percentage 
of the initial intracellular protein radioactivity (Figure 
4.9). The proteolytic rate o f 1.5 - 1.7% per hour was similar 
to that reported by other work ers (80). 
4.3.2.2. Intracellular proteolysis in the presence of 
human serum. 
The substitution of horse seru m by 10% human control serum, 
present on the cell layers following the labelling period, 
did not significantly alter the proteolysis rates of the 
cells (Figure 4.9). Serum from 3 weight-losing cancer 
patients at 10% final concentration did not show any differ-
ence in percent proteolysis when compared with the effect of 
serum derived from patients without cancer (Figure 4.10). 
The proteolytic rate was 1.5% per hour. 
Increasing the serum substitution to 15% and 40% final conc-
entration also caused no significant differences to appear 
in comparisons with 10% horse serum, both in the case of 
serum from cancer and "noncancer" patients (Figure 4.11). 
Adding 40% "human control" serum did cause a slight decrease 

















Figure 4.9. Intracellular basal proteolysis and 
proteolysis of cell layers exposed to 
serum from a control patient, with 
increasing time. 
% Intracellular proteolysis of cell layers exposed to 
( ! ) 10% human control serum, ( I ) 10% horse serum (where 
the serum is present for the period post-labelling of 
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Figure 4.10. Intracellular proteolysis of cell layers 
in the presence of serum from weight-
losing cancer patients. 
Intracellular proteolysis of cell layers in the presence 
of 10% serum from "non-cancer" patient (I) and serum 
from 4 weight-losing cancer patients: 
( l::,,- l::,,) cancer patient 1 
(A-A) II II 2 
(o- o) II II 3 
<•-•) II II 4 
Each point is the mean of 2 dishes and results are expressed 
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Figure 4.11. Intracellular proteolysis of cell layers 
exposed to increasing concentrations of 
serum from both cancer and non-cancer 
patients. 
Concentrations of human serum increased to 15% and 40%; 
non- cancer patient (!).-!). 
losing cancer patient 
patient (2) (0-0 : 15%; 
15%) · ' ' (A-A , 40%),and weight-
( 1) (o-o 15%; 
@-@ : 40%). 
• - • : 40%), and 
Intracellular 
proteolysis under basal conditions; (1-1), 10% horse serum. 
Each point is the mean of 2 dishes and results expressed 
as a percentage of the proteolysis occurring. 
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substitution of one cancer patient serum sample. This may 
indicate some sort of effect arising due to the increased 
concentration of the serum. 
Placing serum from a weight-losing cancer patient on the 
cell layers for a lon ger time period caused a more marked 
effect (Figure 4.1 2 ). Cell la y ers were exposed to serum 
from t h e same canc e r patient at 10% final concentration for 
the 24 h r pre-label p e riod; t h e post-la bel period or both 
pre- and post-label period. Th e longer exposure to serum 
from the cancer pati ent showed an increase of 20% in the 
percent proteolysis of the cell layers, when compared with 
those cell layers exposed for shorter periods of time. The 
presence of serum from cancer patients during the labelling 
period did not alt e r the total label incorporation into 
protein in 16 hr. 
4.3.2.3. Accelerated intracellular pro t eolysis. 
Under conditions of ''starvation" i.e. in minimal medium, an 
increase of almost 50% (48%) in the percentage proteolysis 
was seen (Figure 4.13), when compared with the percentage 
proteolysis under standard conditions. This represents a 
normal proteolytic response to a physiological stress, and 
has been found by oth er workers (80). 
4.3.2.4. Intracellular proteolysis in the presence of 
inhibiting factors. 
The addition of exogenous factors known to inhibit proteolysis 
unexpectedly caused a stimulatory effect of 20% in percentage 
proteolysis compared with the percentage proteolysis in un-
supplemented medium~ The similarity between the increase 
effected by these factors and by the serum exposed to the cell 
layers for a longer time period may indicate that increases 
observed with serum were not true increases but artefacts 
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Figure 4.13. Response of system to starvation and addition 
of proteolytic inhibiting factor. 
Intracellular proteolysis of cell layers under basal condi-
tions (1-1); under "starvation" conditions, i.e. minimal 
medium(!-!) and under basal conditions+ insulin (0,1 units/ 
ml), glucose (10 mM) and branched chain amino acids at xS 
plasma concentration (a-a). Each point is the mean of 2 dishes. 




The two independent heterologous in vitro proteolysis assay 
systems failed to unequivocally demonstrate the absence or 
presence of proteolytic factor(s) in the serum of cachectic 
cancer patients. 
The rat diaphragm assay is well-characterized (73,75,76,77, 
79) and in my hands satisfied the functional criteria for 
proteolysis determinations established by other workers. The 
system appears, however, to be far from ideal for the sophis-
ticated proteolysis determinations required in order to detect 
any tumour-produced ectopic factor(s). The system failed to 
respond to physiological levels of exogenous hormones or to 
endogenous hormones present in the serum of physiologically 
manipulated rats. 
The hormones may not act at the muscle cell level or alter-
nately the diaphragm is not sufficiently sensitive to res-
pond to the effects. Different skeletal muscles differ in 
the relative proportions of varying fibre types and therefore 
can differ appreciably in their metabolic, endocrinological 
and pharmacological responses (75). The diaphrag~ comprised 
predominantly of red fibres, may therefore not respond to a 
variety of stimuli that other muscle types might do. The 
failure to demonstrate any tumour-associated proteolytic 
effect, both with human serum and with a homologous system 
using medium from transformed cell cultures (a rat cell line) 
not only suggests insensitivity of the diaphragm muscle but 
may have been an artefact of the desalting procedure. The 
cell culture proteolysis system was optimally functional and 
satisfied some of these unsuitable aspects of the diaphragm 
assaysystem. However, this heterologous system also failed 
to indicate any proteolytic tendency of "cancer" serum, while 
proving responsive to other proteolytic stimuli, such as 
"starvation". 
This suggests the lack of a suitable system with which to 
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test these effects and which will need to be established and 
characterized before it can be said that no ectopic factor(s) 
exists in the serum of cachectic cancer patients. 
A homologous human system suing human .muscle biopsies in a 
similar in vitro assay to the rat diaphragm, is technically 
difficult, but has been reported (21). Teasing of the muscle 
fibres and sampling of the muscle pieces from various patients, 
to obtain similar and reproducible effects is extremely dif-
ficult and not without its pitfalls. The cachectic tumour 
model of Strain et al (9) appears thus far the most satis-
factory system to work with. Providing cachexia-prqducing 
tumours can be successfully xenografted into experimental 
animals, extensive and comprehensive investigations into 




HAS SERUM FROM CACHECTIC CANCER PATIENTS A LIPOLYTIC 
EFFECT ON ADIPOSE TISSUE? USE OF A HETEROLOGOUS IN 
VITRO ASSAY SYSTEM 
5.1. INTRODUCTION 
Loss of body fat is commonly associated with experimental 
(24,25,27) and human cancer (7,14,26), as has been reviewed 
in -Chapter 1. 
The study of lipid loss in cancer has frequently raised the 
question of a tumour-induced humoral factor(s) which may 
stimulate adipose tissue lipolysis. Alternately, tumours 
have been considered possibly to cause the host to produce 
lipolytic hormones, to provide perhaps, a fuel source. 
In this chapter is reported an investigation on the ability 
of serum from cancer patients (both weight-losing and non-
weight-losing cancer patient groups) to stimulate adipose 
tissue lipolysis, in a heterologous assay. 
Patient selection and the preparation of serum samples were 
conducted as described in 4.2.1.3.; experiments on in vitro 
proteolysis and lipolysis were run concurrently, using the 
same fresh serum samples. This parallel approach applied 
to all conditions studied. 
Rat epididyrnal fat pads provided a means for directly com-
paring the effects of serum from cancer patients with serum 
from control patients, on lipolysis of fragments of adipose 
tissue derived from single experimental animals. By ex-
pressing the results as a percentage effect, mean values 
of paired experiments done with different animals could be 
obtained. This approach was applied to all comparisons 
made in this chapter. 
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5.2. METHODS 
5.2.1. Experimental Procedur e . 
(Note: See Appendix for suppliers of important materials). 
Long-Evans male rats of betwe en 200-250 g were routinely 
used as adipose tissue donors. The rats were killed by 
cervical dislocation. The epididymal fat pads were excised 
and sections of the fat pad (around 150-200 mg each) were 
cut directly into preincubation flasks containing 4 mls KRB-
buffer (see 4.2.1.1.), gassed with 95% o 2 - 5% CO 2 , and pre-
incubated for 15 mins, at 37°C, with shaking. The fat 
pieces were then transferred to incubation flasks containing 
2 mls of incubation medium, pH 7.4. with 0.2% bovine serum 
albumin (BSA) and 12 mM glucos e present under all incubation 
conditions. 
Additions of various hormones ~e re made in the following 
concentration ranges: insulin: 0.2 - 0.4 units/ml; 
adrenalin: 10-8 , 5xlo- 7 , 10- 7 , 5xlo- 7 • 10- 6 Molar. 
The incubation flasks, after gassing, were incubated with 
shaking at 37°c, for 90 mins (unless otherwise stated), 
after which time the fat pads were removed, blotted and 
weighed. The medium was depro t einized with 0.4 mls 20% 
perchloric acid and the supernatant neutralized with 1 ml 
3M KHC0
3
, on ice. After centrifugation at 1200 g for 
15 mins, on a Beckman TJ-6R cen t rifuge at o0 c, an aliquot 
of the supernatant was assayed for glycerol content by an 
enzymatic procedure. 
5.2.2. Assay for Glycerol. 
Scheme: 
(i) glycerokinase Glycerol+ ATP ~L-glycerol-3-phosphate + ADP 
lactate 
(ii) PEP+ ADP pyruvate kinas e ~Pyruvate dehyd~se Lactate 
H + NADH NAD+ 
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The disappearance of NADH at 340 nm was recorded on a 
Beckman MSL spectrophotometer, and the micromoles of 
glycerol derived from the molar extinction coefficient of 
NADH at 340 nm in a 1 cm light path and having 1 ml volume 
in the cuvette. 
The procedure was as follows:- a mixture containing tri-
ethanolamine (TEA) 0~2 M; Mg2so 4 , 0.1 M; KCl, 1 M; ATP, 
4 mM; PEP, 10 mM; NADH, 2 mM (final concentrations) was 
placed in disposable Kartell cuvettes with pyruvate kinase 
(3.5 units); lactate dehydrogenase (2~0 units) and an 
aliquot of deproteinized medium to a final volume of 1 ml. 
After mixing, the absorbance at 340 nm, after 10 mins, was 
recorded to give (E1 ). Glycerokinase (1,0 unit) was then 
added, with mixing, to each cuvette; after 45 mins at room 
temperature, the absorbance at 340 nm was read to give (E 2 ). 
The change in absorbance ~E i.e. (E1 -E 2 ) was determined, 
corrected for . the blank (Lili obtained in a cuvette containing 
the enzyme system as described, with buffer but no added 
glycerol), and the micromoles of glycerol in each sample 
were then determined from the corrected ~E using the molar 
extinction coefficient of NADH at 340 nm. The rate of 
lipolysis was expressed as the total amount of glycerol 
released into the medium (micromoles) per gram wet tissue 
weight per hour. A standard glycerol curve (50; 100; 150 
nmoles) was run concurrently with each glycerol determina-
tion, as a check on the sensitivity and reproducibility of 
the assay system. 
5.2.3. Serum Samples (human and rat) and Transformed Cell 
Culture Medium Samples. 
The selection, collection and preparation of the above were 
exactly as described in (4.2.1.3; 4.2.1.4; 4.2.1.5), the 
onlyp and most important difference being that "whole" artd 
not desalted serum (or cell culture medium) was used. 
A glycerol blank (representing the content of the added 
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serum cell culture or medium) was determined for each incu-
bation condition (i.e. the glycerol content of the incubation 
flask, minus tissue) over 90 mins in incubation and was sub-
tracted from the experimental glycerol value to provide a 
corrected amount of glycerol release from the tissue. 
5.3. RESULTS 
5.3.1. Optimalization of the Assay. 
Kralovic et al (25), performing experiments similar to the 
ones being reported, detected appreciable lipase enzyme · 
activity in serum at pH 7.4. This complicated the inter-
pretation of their results since they measured free fatty 
acid release and found the apparent increase in this release 
to arise from lipase activity of the added serum. 
In this work, the rate of lipolysis was assessed by measuring 
the amountof glycerol released, from adipose tissue, into the 
incubation medium. Measurement of glycerol offered addition-
al advantages: it is not insoluble and does not require a 
carrier, such as albumin; it is not reutilized by adipose 
tissue since glycerokinase is absent in this tissue (84). 
The accumulation of glycerol is a valid reflection of the 
net rate of lipolysis (85), although the rate of accumulation 
in the medium does not necessarily reflect the true total 
rate of production because of dysequilibrium which may arise 
between tissue glycerol and medium (86). The glycerol con-
tent of freshly excised tissue is negligible, however, in 
relation to that found in the medium in incubation experi-
ments (85), and thus for the purpose of this study, the 
glycerol content in the medium was taken to represent net 
lipolysis occurring in the system, and tissue glycerol 
measurements were not routinely performed (85). 
Incubation in the presence of glucose and albumin did not 
affect glycerol release from t h e medium (85,86). Glucose 
was added for the following reasons: the amount of this 
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metabolite was expected to vary in the serum samples added; 
glucose also provides a source of a-glycerophosphate for 
the reesterification of tissue free fatty acids such that 
these do not become toxic to the adipocytes of the tissue. 
The presence of albumin also served to prevent toxic accumu-
lation of tissue free fatty acids, with time in incubation 
(absence of albumin from the medium leads to free fatty acid 
accumulation in the tis sue ( 84)). 
The enzymatic method for glycerol determination provided a 
simple, reproducible means of measuring glycerol. The 
glycerol standard curve (Figure 5.1) taken as the mean of 
8 separate determinations, was always linear. 
The error involved in the entire system i.e. tissue excision, 
incubation, medium deproteinization and enzymatic glycerol 
determination, was around 10%, variations being caused 
mainly by harsh handling of the fragile epididymal fat pads. 
In order to determine any changes in the rate _ of glycerol 
release during 2 hours of incubation, pairs . of tissue frag-
ments from single experimental animals were incubated for 
periods of 1 and 2 hr (Figure 5.2). Release of glycerol 
(µmoles glycerol released/gram wet tissue weight) was linear 
for up to 2 hr; 90 min incubation periodsv.ere accordingly 
chosen for all further assays. 
Glycerol release in µmoles per hour was linear with increasing 
wet tissue weight of adipose tissue (Figure 5.3)~ 
The use of adipose tissue from fasted rats was considered 
as a possible means of increasing the rate of glycerol 
release from tissue, such that background serum glycerol 
levels would be negligible in comparison, and "whole" serum 
could be used. Adipose tissue from fasted rats (90-hour 
fast) released glycerol at a higher rate than did adipose 
tissue from fed rats (Table 5.1.), but this higher lipolytic 
0 ,7.! 
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Figure 5.1. Standard curve of glycerol determined by 
enzymatic assay. 
Each point is the mean ±S.E. of 8 determinations. 
Glycerol was determined using the molar extinction 
coefficient of NADH at 34 0 nm, in a 1 ml volume for 
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Figure 5.2. Glycerol release from adipose tissue 
with increasing time in incubation. 
Each point is the mean ±S.E. of 2 separate determina-
tions (using tissue from one animal) in KRB-buffer 
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Figure 5.3. Glycerol release from adipose tissue as . 
a function of increasing wet tissue weight. 
Each point represents the glycerol release (µmoles/hr) 
of a ~eparate tissue piece from a single animal. 
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TABLE ,5 .1. 
GLYCEROL RELE·ASE FROM EPIDIDYMAL FAT PADS FROM FED 
AND FASTED (90-HR) RATS 
Epididymal fat pad donor 
Fed rat ................ . 
90-hr fasted rat ........ 
Lipolytic rate as µmoles 
glycerol/g/hr 
0.64 + 0.02 
1. 60 + 0. 0 5 
Lipolytic rate as the mean+ S.E. for 7 animals in each 
p hysiological state; a duplicate sample from each 
animal. 
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rate was not linear over 2 hr of incubation (Figure 5.4). 
Accordingly, epididymal fat pads from fed rats were used, 
pieces of 150-200 mg providing sufficient glycerol release 
during 90 min incubation to accommoda~e the background serum 
glycerol level of "whole'' seru m. Fed rats provided a con-
trol physiological state ~n which to test the effects of the 
serum samples (as discussed in 4.2.2.1). 
5.3.2. Response of the System to Exogenous Hormones. 
The incubation system responded to addition of exogenous 
hormones. Adrenalin stimulated lipolysis in a dose-depend-
ent manner (Figure 5.5.). The greatest stimulation occured 
between concentrations of 10- 7 M - 10- 6 M, giving the curve 
a sigmoid shape. Other workers (87) have noted a bimodal 
dose response curve with increa sing adrenalin concentrations, 
-6 -3 around 10 M - 10 M, a sharp increase in glycerol release 
occurring just below 10- 6 M. 
Insulin, at concentrations between 0.2 - 0.4 units/ml, gave 
a slight inhibition of about 8 %, in internally paired com-
parisons with tissue from 10 animals; this was not outside 
the error of the system. Some variability may have been 
due to inactivation of the hor mone prior to its addition 
to the incubation flask; commercial preparations of insulin 
contain glycerol to stabilize the hormone and it was neces-
sary to remove this high background glycerol by gel filtra-
tion. Insulin, in medium containing glucose, has been 
found to cause mild inhibition of glycerol release, but a 
greater inhibition of free fatty acid release (84). Insulin 
inhibition of adrenalin-stimulated lipolysis is well reported 
and substantiated (84,86,87). 
5.3.3. Response of the System to Human Serum (Cachectic 
cancer, cancer, control patient serum). 









figure 5.4. Release of glycerol from adipose tissue 
of a fasted(!) and fed<•> rat. 
Each point is the mean ±S.E. for 2 rats in each physio-
logical state, where each time course describes data 
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Figure 5.5. Effect of adrenalin on glycerol release from 
adipose tissue in vitro. 
Each point is the mean ±S.E. of 2 animals, where the% 
stimulation was determined for tissue from the same animal, 
and the mean then deterined. The% stimulation= 
lipolytic rate in adrenalin lipolytic rate in KRB-buffer 
lipolytic rate in KRB-buffer 
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1:1 KRB-buffer : serum) ranged from 10-80 nmoles, and 
comprised one-quarter to one-third of the total medium 
glycerol after 90 min incubation. The serum did not gene-
rate glycerol over 2 hours in incubation. 
Serum from a fed control patient caused 24 ± 7.0% (mean± S.E.) 
inhibition of glycerol release (Table 5.2), for paired internal 
comparisons with tissue from 3 animals. 
In comparison, serum from a fasted control patient gave a 
higher lipolytic rat e than did serum from the same control 
patient in a fed state (Table 5.3 ) i.e. serum from the fed 
state was more inhibitory than serum from the fasted state. 
Th e difference was 10%, for paired internal comparisons , and 
may have reflected differences in serum insulin levels -
this hormone being present at lower concentrations during 
fasting. Serum samples from fasted patients had higher back -
ground glycerol contents. Serum samples from fed patients 
were accordingly, routinely us ed (see 4.2.2.2.). 
Serum from cachectic cancer patients and from cancer patients 
having no evidence of weight loss, showed an inhibition of 
glycerol release compared with matched control patient serum 
samples (Table 5.4). The mean percentage inhibition deter-
mined for internally paired comparisons between cancer and 
control sera was 14 ± 3.4% (mean+ S.E.) for weight-losing 
cancer patients, and 17 ± 1.8% (mean+ S.E.) for non-weight-
losing cancer patients (Table 5.5 ). The variation between 
cancer groups (i.e. 17% and 14% inhibition) was slight and 
may have reflected varying hormone levels in the serum 
samples. The difference between addition of cancer-derived 
and control serum was evidently not adequate to indicate a 
cancer-specific effect (regardl ess of weight loss). If the 
effect was in fact real, it was uniformly slight and not 
related specifically to the cachectic condition of cancer 
patients. The effect, in any case, was one of inhibition, 
and not stimulation, of lipolysis. 
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TABLE 5.2. 
GLYCEROL RELEASE IN KRB-BUFFER AND KRB-BUFFER CONTAINING 
HUMAN SERUM (NON-CANCER CONTROLS) 
Incubation condition 
KRB-buffer ••••...... 




o. 54 + 0.04 
0.40 + 0.04 
Lipolytic rate as the mean± S . E. for 3 animals. The 
comparison was performed in "inte rnal, paired" experiments 
to determine the percentage effect of serum presence in 
the medium. 
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TABLE 5. 3. 
GLYCEROL RELEASE FROM TISSUE IN CUBATED IN SERUM FROM 
A FED OR FASTED CONTROL PATIENT 
Serum source 
Fed control patient ..... 
Fasted control patient .. 
Lipolytic rate 
(i.i rnoles/g/hr) 
0.58 + 0.04 
O. 61 + O. 04 
The r ates are expressed as t he mean+ S.E. of paired 
duplicate internal comparison s . 
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TABLE 5.4. 
GLYCEROL RELEASE FROM ADIPOSE TISSUE INCUBATED IN 
SERUM FROM A WEIGHT-LOSING AND A NON-WEIGHT-LOSING 










(µm oles/ g/hr) 
0. 42 + 0. 01 
0 .53 + 0.0 2 
0.70 + 0.03 
0 .77 + 0.03 
Results are the mean± S.E. for 5 paired sets of 
weight-losing cancer: control, patient sera and 
non-weight-losing cancer:control patient sera where 
each set of cancer:control serum samples was per-
formed in duplicate. 
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TABLE 5.5. 
PERCENTAGE STIMULATION OF LIPOLYTIC RATE CAUSED 
BY CANCER-DERIVED ·COMPARED WITH CONTROL SERUM 
Serum source 
Weight-1 o sing cancer 
patient . . . . . . . . . . 
Non-weight-losing 
cancer patient ... 
% Stimulation in 
lipolytic rate 
-14 + 3.4 
-17 + 1.8 
As the mean± S.E. where the % stimulation= 
Lipolytic rate in cancer serum - lipolytic rate in control 
serum 
Lipolytic rate in control serum 
determined for paired internal comparisons and the mean was 
taken of 10 determinations in each cancer serum type. 
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In Chapter 2 of this thesis, evidence was given to show that 
breast cancer patients have increased fat areas compared 
with control patients, and the present ideas relating diet 
and breast cancer (see Chapters 1 and 2) may be reflected 
in the fat-conserving effect seen with serum from breast 
cancer patients i.e. the non-weight-losing cancer patient 
group. The fat-conservin g effect seen in the cachectic 
cancer patient group was contrary to what was expected in 
the light of present ideas re v iewed in Chapter 1, and the 
evidenc e presented in Chapter 2 . It is possible that 
cachectic cancer patients, losing increased body fat, mount 
a host response involving the production of hormones which 
conserve lipid stores. 
5.3.4. Response of the System to Mediu m from Transformed 
Cell Cultur e s. 
The possibility of a lipoly t i c factor produced by a mali gnan t 
cell line, which would cause increased lipolysis in this in 
vitro system, was inve stigated usin g medium from a trans-
formed rat cell line (R 9c1 10T cell cultures) (refer 4.2.1.5.) 
in which the factor of a species difference was eliminated 
(i.e. a malignant rat cell lin e producing factors effective 
against rat tissue). 
Medium from transformed and control cell cultures caused 
substantial inhibition of glycerol release (Table 5.6) which 
was most marked using medium from the transformed cell layers. 
It did not appear to be a medium effect but rather an effect 
specific to the transformed cell cultures. This effect was 
not investigated further since it was a diversion from the 
primary investigation, and thus the exact reason for this 
inhibition is not known. It may be that as the transformed 
cells had a greater rate of division, there would be more 
cellsper dish which would be better able to "condition" the 
medium (e. g . with metabolites, by-products and waste products) 
such that glycerol release fro m adipose tissue in the presence 
of this medium in vitro was reduced by 68%. The modulation 
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TABLE 5. 6. 
GLYCEROL RELEASE FROM ADIPOSE TISSUE I NCUBATED WITH 
MEDIUM FROM TRANSFORMED CELL CULTURES 
Incubation condition Lipol ytic rate 
(µmoles/ g/hr) 
% Inhi bi t ion 
KRB- buff er .....••.•. 
Medium T KRB-buffer 
Medium T KRB-buffer 
Medium 
Where 
KRB-buff e r 
(1 1) 
Medium T = medium 
Medium = medium 
0.62 + 0.03 
68 + 1.2 
0.18 + 0.07 
0 . 20 + 0.02 
54 + 5.0 
0.47 + 0.07 




from untransformed cell cultures 
(R9Cl10). 
The lipolytic rate was the mean+ S.E. for 2 animals in 
duplicate internal comparison s . 
The% inhibition= 
Lipolytic rate in KRB-buffer - lipolytic rate in Medium T 
Lipolytic rate in KRB-buffer 
or alternately 
Lipolytic rate in Medium - lipoly"tic rate in Medium ,T 
Lipolytic rate in Medium 
and is the mean of separately determined internal comparisons. 
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of these cells may have caused metabolic changes, as yet not 
apparent, that would cause the inhibitory effect of the 
medium. 
5.3.5. Response of the System to Rat Serum. 
As described for the proteolysis system in Chapter 4, the 
response of this in vitro lipolysis system to rat serum (both 
control rat serum and physiolo gically modulated rat serum) 
was investigated. Control rat serum had a negligible 
inhibitory effect on the KRB-buffer system (4% as determined 
in paired internal comparisons with 4 animals) (Table 5.7). 
Comparing serum from fed and fas ted rats, no differences 
were observed with serum fro m fe d rats and from rats fasted 
for 90 hours. Serum from 13 0 i r fasted rats increased the 
lipolytic rate by 40 ± 7.1% ( ~ean ± S.E.) compared with the 
rate using serum from fed ani mals (Figure 5.6). This effect 
was greater than that seen witi serum from fasted humans, and 
may indicate a response of ra t t issue to rat serum i.e. a 
species barrier to adipose tissue response in vitro. 
The other hormone treatments i.e. Alloxan-induced diabetes; 
hydrocortisone treatment, eithe r alone or coupled with 
130-hr starvation, yielded serum that reduced the lipolytic 
~ate of adipose tissue, when compared internally, with control 
fed rat serum (Figure 5.7). Th e 16 ± 7.4% (mean± S.E.) 
inhibition in diabetic rat serum is not likely to be an 
insulin effect. The insulin in the serum would be negli-
gible and the serum would be expected to stimulate lipolysis. 
The increased glucose in the serum would not have affected 
the glycerol release directly. 
Hydrocortisone treatment yielded serum that gave the greatest 
inhibitory effect, which was diminished, but not eliminated, 
by concomitant starvation of the serum donor rat. The hydro-
cortisone influence appeared greater than the starvation in-
fluence (refer to Figure 5.6). Thyrotoxic rats gave serum 
that caused over 100% stimulation of lipolysis, in paired 
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TABLE 5. 7. 
GLYCEROL RELEASE FROM ADIPOSE TISSUE INCUBATED WITH 
CONTROL RAT SERUM 
Incubation condition 
KRB-buffer 
KRB-buffer : rat serum 
(1:1) 
Lipolytic rate 
(µ moles /g/hr) 
0.51 + 0.03 
0.46 .±. 0.07 
Lipolytic rate is the mean± S.E . for 4 controls. 
Each determination was performed by paired internal 
comparison to allow direct comparison of the% 
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Figure 5.7. Release of glycerol from adipose tissue 
incubated in the presence of serum from rats 
under various hormonal treatments. 
Each value is the mean rate of 2 separate determinations, 
where (a) and (b) were each performed within one animal. 
The rat serum source was as follows: 
(o) - fed control rats 
(~) - alloxan-treated rats 
( If) ) - hydrocortisone-treated rats 
(~) - hydrocortisone-treated + 130 hr fasted rats 








internal comparisons with control rat serum. This is in 
accord with what one would expect. knowing the stimulatory 
effect of thyroxine on lipolysis. Experiments of this 
nature rely on the assumption that animals react to hormone 
treatments to produce serum which cont.ains some factor 
(hormone or metabolite) in sufficient quantity, absent or 
present ~ithin physiological limits) to produce responses 
in vitro in incubation systems. 
One would expect increased lipolysis rates in vivo to arise 
from the treatments described. However. different animals 
do not always respond as expected (?8.82) and if they did 
respond. the substances produc ed by the response may be in 
amounts which manifest overall as zero net change in lipo-
lysis rate, in vitro. One can therefore not predic t con-
fidently any effect with this type of · experiment. 
The system did, however, show a response to rat serum as 
evidence of its functional capacity and sensitivity. 
5.4. DISCUSSION 
The question of whether a lipolytic factor is present in 
the serum of cancer patients remains unanswered. Previous 
worker? using similar in vitro systems. were unable to reach 
any conclusion regarding the lipolytic tendencies of serum, 
both from tumour-induced rats (25) and human cancer patients 
(22,29). This indicates the lack of a suitable system with 
which comprehensively to investigate this problem in order 
to reach a decision. 
In my hands, epididymal fat pads released glycerol in a 
linear manner, in vitro, for 2 hours and were responsive 
to exogenous hormones. 
The responses to added serum, both from humans and from rats, 
were unfortunately difficult to interpret. This may indicate 
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the need to use a homologous assay system. 
A human mammary adipose cell line may provide a suitable 
human system for human cancer serum investigations. Human 
adipose tissue biopsies would not be feasible to isolate 
or incubate in vitro. 
Qualitative in vivo lipolysis studies on cancer patients 
are somewhat difficult to perform and very complex in 
character. 
The tumour model of Strain et al ( 9) remains the most 
suitable system yet reported for cachectic cancer studies, 
provided the cachexia causing tumours can be excised and 
xenografted successfully in animals. Adipose tissue can 
be isolated from these weight-losing mice hosts, and lipo-
lytic rates established in vitro and compared with controls. 
In vivo mouse host studies could also be done. ---
The serum of mouse hosts could be fractionated to investigate 
tumour factor(s) or alternately to qualitate host hormones 
and thus establish any increase in these compared to normal, 
or to assess if normal responses to stress situations were 
applicable. 
This may comprehensively answer the question of ectopic 
hormone production or alternately provide evidence for the 




This study ~~s failed to subs t antiate the proposal of a 
tumour-produced ectopic factor(s), which could cause cachexia 
of cancer patients. Nevertheless, we have not conclusively 
ruled out the possibility that such a factor(s) exists. 
Other workers investigating t his question and using minor 
variations of the same in vitro assay systems, have also 
not provided equivocal eviden ce for ectopic factor production 
(see Chapter 1). 
It is my opinion that present in vitro methods used to tackle 
this question are inadequate, and thatthe field of cancer 
cachexia lacks a clear-cut in tense investigation into the 
frequency, tumour type and ex ten t of disease associated with 
this condition. A clearer un de rstanding epidemiologically 
into cancer cachexia, together with further investigations, 
using the in vivo human model, into changes in serum amino 
acids, including 3-Methylhistidine, metabolites, minerals . and 
waste products such as creatinine, would be invaluable in 
aiding biochemical investigations, as revealed by Chapters 
2 and J. 
Present in vitro assay systems yield equivocal data and rely 
on a vast number of assumptions that may not be justified. 
One such important consideration is the relevance of animal 
models: induction of cachexia in experimental animals by 
animal carcinomas e.g. Krebs-2, Walker 256, etc., may be far 
removed from the human system. Unfortunately, because of 
their convenience, these methods continue to be widely used. 
The use of serum from cachectic cancer patients on experi-
mental animal models, in vivo provides a more direct approach 
but is plagued by the question of possible inactivation of a 
factor(s), species barriers, and the general sensitivity of 
the system with respect to the concentration of factor(s) 
and length of time required to observe an effect. The model 
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of Strain et al, as discussed in sections 4.4, 5.4, is thus 
far the most feasible and advanced system, which remains 
convenient for a comprehensive investigation into this 
area. Until a system is available to provide exact, re-
producible data, and which could become widely used, the 
proposal of ectopic factor production remains equivocal, 




The following chemical suppliers were used: 




Boots Company (SA) Pty Ltd 
Isando, Transvaal. 
Eli Lilly & Co., 
Indianapolis, USA 
Gibco Laboratories, 
New York, USA 
Merck, Darmstadt, 
Germany 
Miles Laboratories (Pty) Ltd 
Epping, S.A. 
New England Nuclear, 
Cape Town, S.A. 
Pharmacia Fine Chemicals 
Uppsala, Sweden 
Sigma Chemicals Co. 
St Louis, USA 
Alloxan 
Glycerokinase; lactate 
dehydrogenase; pyruvate kinase. 
Insulin. 
Glucagon 
Dulbeccos Modified Eagles 
Medium, Medium 199. 
D(-1) Glucose. 
Bovine serum albumin. 
L-[H3]-phenylalanine. 
Sephadex G-25 (medium) 





1-leucine; L-isoleucine; L-valine; 
1-tyrosine; L-phenylalanine. 





Animals: Male Long Evans rats used and supplied by 
Physiology Animal House, UCT Medical School. 
Chick Embryo Extract: Prepared from 11-day chick embryos, 
under sterile conditions, filtered and frozen. Before it 
was added to the media, the thawed extract was centrifuged 
at 400 g to remove insoluble material. 
Horse serum: Prepared from freshly collected blood obtained 
from the State Vaccine Institute, Cape Town. 
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